1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999
COMMISSION FILE NO. 1-9767
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
DELAWARE 94-2579751
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
9162 ETON AVENUE, CHATSWORTH, CALIFORNIA 91311
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
TELEPHONE NUMBER: (818) 709-1244
SECURITIES REGISTERED PURSUANT TO
SECTION 12(b) OF THE ACT:
COMMON STOCK (AMERICAN STOCK EXCHANGE)
SECURITIES REGISTERED PURSUANT TO
SECTION 12(g) OF THE ACT:
NONE
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. ___
On March 15, 2000, the aggregate market value of the shares of Common
Stock held by non-affiliates of the Registrant was approximately $19.6 million
based upon the closing price of $2-13/16 per share of Common Stock as reported
on the American Stock Exchange. Solely for the purpose of determining
"non-affiliates" in this context, shares of Common Stock held by each officer
and director and by each person who owns 5% or more of the outstanding Common
Stock have been excluded. This determination of affiliate status is not
necessarily a determination for other purposes.
The Registrant had 9,395,920 shares of Common Stock outstanding on March
15, 2000.
Part III incorporates information by reference from the Proxy Statement
for the Registrant's 2000 Annual Meeting of Stockholders.
2
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
FORM 10-K ANNUAL REPORT
FISCAL YEAR ENDED DECEMBER 31, 1999
PART I
Item 1. Business.....................................................................................1
Item 2. Properties...................................................................................9
Item 3. Legal Proceedings...........................................................................10
Item 4. Submission of Matters to a Vote of Security Holders.........................................10
PART II
Item 5. Market for the Registrant's Common Stock and Related Stockholder Matters....................10
Item 6. Selected Financial Data.....................................................................11
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.......12
Item 7A. Quantitative and Qualitative Disclosures About Market Risk..................................19
Item 8. Financial Statements and Supplementary Data.................................................19
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure........19
PART III
Item 10. Directors and Executive Officers of the Registrant..........................................19
Item 11. Executive Compensation......................................................................19
Item 12. Security Ownership of Certain Beneficial Owners and Management..............................20
Item 13. Certain Relationships and Related Transactions..............................................20
PART IV
Item 14. Exhibits, Financial Statements Schedules, and Reports on Form 8-K...........................20
3
PART I
ITEM 1. BUSINESS
A glossary of selected technical terms is included at the end of this
section. Please review the glossary before reading the description of business.
International Remote Imaging Systems, Inc. and its subsidiaries are sometimes
referred to as IRIS, the Company, we, our or us.
INTRODUCTION
In March of 2000, we entered into a letter of intent to sell
Perceptive Scientific Instruments, our genetic analysis business. In light of
our plans to sell Perceptive Scientific Instruments, we are treating this
business as a discontinued operation for accounting purposes, and we have
removed it from most of the discussion and financial information in this Annual
Report. For a further discussion of our plans to sell this business, please see
the section entitled "Management's Discussion and Analysis of Financial
Condition and Results of Operations--Discontinued Business Operations" beginning
on p. 17.
OVERVIEW
We design, develop, manufacture and market in vitro diagnostic, or IVD,
imaging systems for urinalysis testing based on patented and proprietary
automated intelligent microscopy, or AIM, technology for automating microscopic
procedures performed in clinical laboratories, as well as special purpose
centrifuges and other small instruments. Our microscopy technology combines our
capabilities in automated specimen presentation, including our patented
slideless microscope, and proprietary high-speed digital processing hardware and
software to classify and present images of microscopic particles in easy-to-view
displays. Our systems provide customers with better and more rapid results and
labor cost-savings over manual methods of performing microscopy. We sell our
products directly and through distributors to hospital and reference clinical
laboratories, as well as to veterinary, physician office and research
laboratories.
We pioneered our first urinalysis system in 1983 when we introduced The
Yellow IRIS family of workstations and we introduced our fourth generation
models, which are faster and easier to use, in 1996. We believe that we are
still the only supplier of laboratory systems which fully automate a complete
urinalysis. Also in 1996, we began to market the Model 900UDx urine pathology
system, which was designed especially for the high-volume testing requirements
of larger laboratories. We also provide ongoing sales of supplies and service
for The Yellow IRIS workstations. Most supplies are purchased under standing
orders and, following an initial one-year warranty period, the majority of
customers purchase annual service contracts.
Through our subsidiary StatSpin, Inc., we manufacture and market a
variety of benchtop centrifuges, small instruments and supplies for the
laboratory market. These products are used primarily for manual specimen
preparation and dedicated applications in cytology, hematology and urinalysis.
They appeal to laboratories and physician offices performing too few tests to
justify the cost of an automated IVD imaging system.
In December 1997, we began distributing the IRIS/Sysmex UF-100 urine
cell analyzer in the United States under an exclusive agreement with its
manufacturer, Sysmex Corporation. We did not have significant sales of the
UF-100 in 1998 or 1999. In September 1998, Sysmex started procedures
to end the exclusive nature of our distribution rights, claiming inadequate
sales performance. We denied these allegations. Sysmex now claims that it has
the right to appoint additional distributors and has announced that its U. S.
subsidiary will distribute the UF-100 in North America. We dispute that Sysmex
has this right and may take legal action. We cannot predict the impact on the
Company of the announcement by Sysmex or any legal action we may take.
We acquired Perceptive Scientific Instruments in July 1996. Its
principal product is the PowerGene family of genetic analyzers -- IVD imaging
systems for karyotyping, DNA probe analysis and comparative genomic
hybridization. In March of 2000, we entered into a letter of intent to sell
this business to a well-known international company for an estimated price of
$2.5 to $5.0 million in cash. For a further discussion of our plans to sell this
business, please see the section entitled "Management's Discussion and Analysis
of Financial Condition and Results of Operations--Discontinued Business
Operations" beginning on p. 17.
1
4
THE INDUSTRY
The healthcare industry has undergone profound changes in the last
decade, and healthcare providers are continually focusing on the most efficient
use of their resources. This goal drives them to reduce costs while
simultaneously improving the outcome potential of patient care. Toward that end,
they must reduce the cost and improve the accuracy of medical tests for
diagnosing and monitoring diseases and improve the reporting of test results.
Medical tests are performed either on the patient or on a specimen
removed from the patient. IVD testing refers to analysis of a specimen removed
from the patient, usually in the clinical laboratory. Many IVD tests rely on
chemical or simple physical measures of specific characteristics of the
specimen. Over the last five decades, the chemical and particle-counting aspects
of these tests have been largely converted from manual methods to automated
instruments, such as clinical chemistry analyzers and blood cell counters.
However, many other IVD tests still require visual examination of the specimen
through a microscope ("microscopy"). Manual microscopy requires numerous steps,
from specimen preparation to visual examination, making the method
labor-intensive, cumbersome, biohazardous, inefficient and imprecise. More time
is spent in performing manual microscopy than in any other IVD testing procedure
in the clinical laboratory. Even so, the vast majority of microscopic procedures
are still performed manually.
The pressure to reduce the costs and improve the accuracy of IVD tests,
together with recent technological developments, have created an opportunity for
automating microscopic procedures. Advances in image processing software,
computer hardware and solid-state cameras have made it possible to uniformly
capture digital images of microscopic specimens and to perform sophisticated
image analysis and classification. The test results can then be electronically
transmitted to the central computer system of the hospital or reference
laboratory for clinical use and billing. The digital images of the specimen can
also be stored in electronic format for future review and, theoretically,
transmitted to remote locations for review by other technologists or
specialists.
THE COMPANY'S STRATEGY
Our current objectives are to enhance our core business in urinalysis,
maintain our technological leadership, continue market penetration of our
existing products, expand the geographic markets for existing products and
increase sales of related supplies and service. We are pursuing these objectives
through the following strategies:
- Enhancement of Existing Product and Continued Market
Penetration. In 1999, we reassessed our business and developed a
new two-year business plan. The plan refocuses our efforts on
our core urinalysis business. The plan emphasizes making major
improvements to The Yellow IRIS urinalysis workstation product
line. Our goal is to develop a lower cost, faster workstation
while simultaneously reducing the amount of technologist time
required to operate it.
- Expanding into New Geographic Markets. We intend to continue to
increase our overseas marketing effort initiated in 1999. Until
1999, we had not made significant international sales of the
Yellow IRIS outside the United States. International markets
have recently begun to consolidate and focus on increased
productivity. We are introducing The Yellow IRIS in selected
overseas markets where consolidation has already occurred and
are developing relationships with local distributors.
- Increasing Sales of Supplies and Service. Once The Yellow IRIS
workstation is installed, we generate significant recurring
revenue from sales of supplies and service for its operation. We
will try to increase these revenues by installing more systems
and by increasing our product offering of supplies for this
system.
- Maintaining Technological Edge. We maintain an active research
and development program to continually enhance our core
technology.
AIM TECHNOLOGY
An effective system for most automated microscopy applications requires
technology for fast, consistent and easily discernable presentation of the
specimen to the microscope ("front end processing") and for rapidly capturing,
analyzing, classifying, enhancing, arranging and displaying images of the
specimen ("back end
2
5
imaging"). Over the past twenty years, we have created and developed our
patented and proprietary AIM technology to address both of these requirements.
Our AIM technology automates all or most of the front end processing in
its IVD imaging systems. For example, traditional urine sediment analysis
requires manual preparation of a slide from the specimen requiring several
steps, including centrifugation followed by carefully positioning, staining and
coverslipping a sample extracted from the specimen. The slide is then placed
under the microscope and manually manipulated and scanned by a technologist.
This procedure is time-consuming, imprecise, and potentially hazardous. In
contrast, our patented slideless microscope, used in The Yellow IRIS, allows
microscopic examination of a moving specimen precisely positioned in a stream of
fluid. This eliminates the need for manual slide preparation, manipulation and
scanning. The slideless microscope positions the specimen to within microns as
it flows past the microscope at high-speed ensheathed in a larger stream of
fluid. This method of alignment, particle orientation, focus and measurement is
called "imaging flow cytometry." We hold a patent on this method, and we are
unaware of any other company which has developed similar technology. For those
IVD tests where imaging flow cytometry does not work well, AIM technology
automates the slide manipulation and scanning process.
Once the specimen is located and presented to the microscope, AIM's back
end imaging automatically captures, digitizes, classifies, organizes and
presents the microscopic images displayed on a video monitor for review by the
medical specialist. These digital images of the specimen can then be stored on
magnetic or optical media for later retrieval, even years later.
PRODUCTS
Urinalysis Systems
Our principal product is The Yellow IRIS family of urinalysis
workstations. This system requires customers to make substantial capital
investments and is designed for sale to clinical laboratories performing a large
number of IVD tests. The Yellow IRIS is used nationwide, including hospitals
affiliated with over 75% of all United States medical schools. This family of
IVD imaging systems consists of three models. Two models can also perform IVD
imaging tests on a number of body fluids other than urine, including
cerebrospinal, peritoneal, pleural, pericardial, synovial and seminal fluids as
well as peritoneal dialyzates and lavages. The third model, the Model 900UDx, is
designed for laboratories testing high numbers of urine specimens. The Yellow
IRIS family of IVD imaging systems currently has list prices ranging from
$100,000 to $195,000.
In the fourth quarter of 1997, we began marketing the IRIS/Sysmex UF-100
urine cell analyzer in the United States. The UF-100, developed in Japan by
Sysmex Corporation, utilizes flow cytometric laser scanning principles to screen
large volumes of urine specimens for the presence of abnormal sediment
compositions. We are the exclusive distributor for the UF-100 in North America
and receive royalties from Sysmex on sales of the UF-100 outside of North
America. The UF-100 currently has a list price in the United States of $125,000.
It provides only the sediment portion of a complete urinalysis.
In September 1998, Sysmex started procedures to end the exclusive nature
of our distribution rights, claiming inadequate sales performance. We disputed
these allegations and began discussions with Sysmex about the pricing and
marketing of the UF-100. Those discussions did not resolve the matter. Sysmex
has asserted the right to appoint additional distributors and has announced that
its U.S. subsidiary will distribute the UF-100 in North America. We dispute that
Sysmex has this right and may take legal action. We cannot predict the impact of
Sysmex's announcement or any legal action we may take. We did not have
significant sales of the UF-100 in 1998 or 1999.
System Supplies and Service
We realize significant recurring revenue from sales of supplies used in
the operation of The Yellow IRIS and from their service and repair. These
supplies include the sheath fluid used to position the particles and cleanse the
system in slideless microscopy and "controls" used in calibrating and monitoring
the performance quality of the systems. We also sell the CHEMSTRIP/IRIStrip for
testing urine chemistry on The Yellow IRIS. CHEMSTRIP/IRIStrips urine test
strips are produced for us through an agreement with Roche Diagnostics.
Small Instruments and Supplies
We also manufacture and market a variety of small instruments and
supplies for the clinical laboratory market through our StatSpin subsidiary.
These products complement our line of urinalysis systems because they appeal
3
6
to smaller laboratories and physician offices that do not perform enough tests
to justify the capital cost of a large automated system. StatSpin's
technologically-advanced small benchtop centrifuges prepare certain biological
specimens for instrumental or microscopic examination in a fraction of the time
required by larger, common laboratory centrifuges. They have proven ideal for
on-demand, point-of-use testing in hospitals, physician's offices and veterinary
laboratories. The basic StatSpin centrifuge unit is adaptable to a variety of
uses through application-specific rotors and consumables. Noted for their
compact design and simple, quiet, and unobtrusive operation, they are
well-suited to laboratories in which technicians are located close to the
equipment. These products also serve integrated healthcare providers who want to
purchase systems and supplies for a variety of clinical settings (both large and
small) from one supplier. This category of products includes special-purpose
centrifuges, digital refractometers for measuring the specific gravity of urine,
the CenSlide System for manual microscopic examination of urine and other
supplies intended primarily for specimen preparation.
Summary of Revenues by Product Line for Each Segment
The following tables present a summary of revenues for each segment by
product line for the three years ended December 31, 1999:
Small
Laboratory
Urinalysis Devices Total
----------- ----------- -----------
For the Year Ended December 31, 1997
Sales of IVD systems $ 5,612,308 $ -- $ 5,612,308
Sales of IVD system supplies and service 10,061,314 -- 10,061,314
Sales of small instruments and supplies -- 4,447,418 4,447,418
Royalty and license revenues 510,920 92,156 603,076
----------- ----------- -----------
Total $16,184,542 $ 4,539,574 $20,724,116
=========== =========== ===========
Small
Laboratory
Urinalysis Devices Total
----------- ----------- -----------
For the Year Ended December 31, 1998
Sales of IVD systems $ 4,985,717 $ -- $ 4,985,717
Sales of IVD system supplies and service 11,785,185 -- 11,785,185
Sales of small instruments and supplies -- 4,345,304 4,345,304
Royalty and license revenues 229,972 235,000 464,972
----------- ----------- -----------
Total $17,000,874 $ 4,580,304 $21,581,178
=========== =========== ===========
Small
Laboratory
Urinalysis Devices Total
----------- ----------- -----------
For the Year Ended December 31, 1999
Sales of IVD systems $ 6,505,821 $ -- $ 6,505,821
Sales of IVD system supplies and service 13,611,676 -- 13,611,676
Sales of small instruments and supplies -- 5,297,385 5,297,385
Royalty and license revenues 310,587 -- 310,587
----------- ----------- -----------
Total $20,428,084 $ 5,297,385 $25,725,469
=========== =========== ===========
BACKLOG
We had a sales backlog for our urinalysis systems of $221,000 at
December 31, 1998 and $341,000 at December 31, 1999. We believe the amount of
backlog at a given date is not necessarily indicative of sales for any
succeeding period.
RESEARCH AND DEVELOPMENT
We maintain an active research and development program to continually
enhance our urinalysis systems and centrifuges. Our product technology
investments (including amounts reimbursed by third parties under research
4
7
and development contracts) totaled $2.5 million in 1997, $2.2 million in 1998
and $1.4 million in 1999. During 1997 and 1998, we upgraded the installed base
of Model 900UDx systems to increase reliability and enhance overall performance.
During 1998, we completed work on software updates to make The Yellow IRIS
family of workstations Y2K compliant. We also continued to refine our AIM
technology, improve the cost-effectiveness of our systems and conduct numerous
other smaller projects during those years.
During 1999, we began a major project to improve The Yellow IRIS
urinalysis workstation product line. We plan to devote most of our research
and development budget to this project. Our goal is to develop a lower cost,
faster workstation while simultaneously reducing the amount of technologist time
required to operate it. During this process, we will incorporate more than 20
years of experience and the latest developments in computer technology. We
also expect to benefit from the increased availability of "off-the-shelf"
components and thereby reduce our dependence on single source suppliers.
We have completed feasibility studies on the proposed improvements. We
believe that this project is important to maintaining our competitive position
in the urinalysis market and that our failure to successfully complete this
project on schedule could have a material and adverse effect on future system
sales.
We have historically received partial funding for research and
development programs through grants from NASA and the National Institutes of
Health, joint development programs with strategic partners, and
Company-sponsored research and development entities. From 1994 to 1996, we
collaborated with Boehringer Mannheim Corporation and Boehringer Mannheim GmbH,
entities subsequently acquired by Roche Diagnostics, in the development of
CHEMSTRIP/IRIStrip urine test strips and the Model 900UDx. Roche is the sole
supplier of CHEMSTRIP/IRIStrip urine test strips and has agreed to supply us
with certain raw materials should we elect to manufacture our own urine test
strips, subject to royalty payments. We were also granted the non-exclusive
right to distribute certain other Roche urinalysis products to hospitals and
commercial laboratories in the United States. We manufacture the Model 900UDx
with Roche providing certain components on an OEM basis at cost. We have
exclusive marketing rights to the Model 900UDx in the United States, Canada and
Taiwan, and non-exclusive rights for the rest of the world outside of Germany
and Italy.
In 1992, we entered into a project with LDA Systems, Inc. for
development of The White IRIS leukocyte differential analyzer and later acquired
LDA for approximately 498,000 shares of our common stock. In 1999, we conducted
a reassessment of our business and developed a new, near-term business plan. We
elected not to include The White IRIS in our new plan, and, as a result, we
wrote off all costs of development and inventory related to The White IRIS in
the third quarter of 1999.
In 1995, we entered into a project with Poly U/A Systems, Inc. for
development of several new products to enhance automated urinalysis.
Subsequently, certain disputes arose with the Poly U/A shareholders. In 1999, we
made a tender offer to acquire all of the outstanding shares of Poly U/A stock
for a package of IRIS securities with an estimated value of up to $1.5 million.
Approximately 79% of the outstanding shares of Poly U/A were tendered in this
transaction. We have recorded the cost of purchasing the Poly U/A stock as a
litigation settlement expense. Poly U/A is now a majority-owned subsidiary of
IRIS, and is accounted for accordingly.
MARKETING AND SALES
In the United States, we sell and service our products through our own
sales and service forces. Sales activities consist of direct sales by field
sales representatives, telemarketing to initiate and aid in pursuing sales
opportunities, logistics support of the field sales representatives and
after-sales support to customers in the operation of their systems. In addition
to our sales activities, we promote our products through advertising in trade
journals, attendance at trade shows and direct mail. All sales of IVD imaging
systems include installation, customer training and a one-year warranty. Our
small instruments, targeted primarily at smaller customers, are sold through
distributors.
5
8
We also maintain a rental program for The Yellow IRIS urinalysis
workstation. Under the terms of the rental agreements, payments generally are
based on the number of tests performed, with a guaranteed monthly minimum
payment. We are responsible for supply and service of the systems.
Alternatively, some customers lease the our systems from medical equipment
leasing companies which, in turn, purchase the systems from us.
In addition, we market most of the supplies used in the operation of The
Yellow IRIS and maintain these systems through our own national service
organization. Service (after a one-year warranty period) is generally sold under
an annual service contract or, less frequently, on a per-call basis.
COMPETITION
Our primary products are The Yellow IRIS family of urinalysis
workstations and the UF-100 urine cell analyzer. The principal competitive
factors in the urinalysis market are cost-per-test, ease of use, and quality of
result. We believe these products compete favorably with regard to these factors
in their respective target markets.
A number of hospitals conduct urine sediment examinations using the Kova
system made by Hycor Biomedical, Inc., as well as several other similar
products, all of which are composed largely of disposable plastic parts. These
products provide a more standardized method of preparing urine sediment for
microscopical examination as opposed to traditional means. While these
disposable products help somewhat to overcome manipulative imprecision, most of
them do so at the added expense of an increased number of disposable parts and
offer little in time savings. One exception is the CenSlide System, which we
acquired in March 1996. This system uses a combination centrifuge tube and
microscope slide, thereby actually eliminating much of the manipulation required
in preparing the urine specimen for microscopic observation. These types of
products are better suited for laboratories performing a small number of
urinalysis tests.
Bayer Diagnostics, Roche Diagnostics, and Dade Behring Corporation sell
lines of urine test strips which are useful in determining the concentration of
various chemical substances often found in urine. Some claims have been made
that the absence of certain results determined with these test strips can
preclude the need for microscopic examinations of some specimens. In 1998, we
obtained FDA clearance to claim of improved performance of The Yellow IRIS over
reagent strip measures in detecting microscopic abnormalities in urine.
Nonetheless, a substantial portion of the urinalysis market has subscribed to
the theory that these test strips can be relied upon to reduce the number of
microscopic examinations. We believe that this is largely due to laboratories'
reacting to cost-cutting pressures. The result is significantly slower growth in
the demand for microscopic examinations at certain hospitals and reference
laboratories.
The Yellow IRIS currently supports only automated test strip readers
supplied by Roche Diagnostics, and some potential customers who have previously
purchased automated test strip readers from Bayer Diagnostics (the dominant
company in the urine test strip business) cannot connect those readers to The
Yellow IRIS. Our ability to modify The Yellow IRIS to support a connection to
test strip readers from Bayer Diagnostics and Dade Behring is subject to
significant restrictions under our existing agreements with Roche Diagnostics.
We are also experiencing increased competitive pressures in the
urinalysis market due to the ongoing consolidation of both hospitals and medical
device suppliers. Large hospital chains and groups of affiliated hospitals are
negotiating comprehensive supply contracts with the larger medical device
suppliers. The larger suppliers often equip an entire laboratory and offer
one-stop shopping for laboratory instruments, supplies and service. In addition,
they typically offer the hospitals annual rebates based on the total volume of
business with the suppliers. These rebates create financial incentives against
purchasing instruments or supplies from others and act as a barrier to the
penetration of hospital laboratories covered by the contract. For example, we
have had significant difficulty in marketing our urinalysis products to
hospitals which are members of Premier Enterprises, a nationwide buying
cooperative of hospitals and healthcare systems. Premier generally establishes a
single vendor for particular product lines and has designated Bayer Diagnostics
as its vendor for urinalysis test strips. Our family of urinalysis workstations,
The Yellow IRIS, uses test strips manufactured for us by Roche Diagnostics and
many Premier affiliated hospitals are reluctant to purchase The Yellow IRIS for
this reason.
6
9
INTELLECTUAL PROPERTY
Our commercial success depends on our ability to protect and maintain
our proprietary rights. We protect our proprietary technology by filing various
patent applications. We have received numerous United States patents for its AIM
technology and related applications, as well as a number of corresponding
foreign patents. These patents also cover developments in image analysis and
blood processing. A number of additional patent applications are pending in the
United States and abroad. These patents also cover image analysis, urine and
blood processing. Also, numerous patents relating to digital refractometers,
centrifuges, automated slide handling and disposable urinalysis products were
acquired in various acquisitions.
We have granted Sysmex a royalty-bearing license to use pre-1989
technology for urine sediment analyzers and non-medical industrial instruments.
We have also granted Dade International a royalty-bearing license to use certain
centrifuge technology.
We have trade secrets and unpatented technology and proprietary
knowledge about the sale, promotion, operation, development and manufacturing of
our products. We have confidentiality agreements with our employees and
consultants to protect these rights.
We claim copyright in our software and the ways in which it assembles
and displays images, and have filed copyright registrations with the United
States Copyright Office. We also own various federally registered trademarks,
including "IRIS," "The Yellow IRIS" and "StatSpin." We own numerous other
registered and unregistered trademarks, and have certain trademark rights in
foreign jurisdictions. We intend to aggressively protect our copyrights and
trademarks.
GOVERNMENT REGULATIONS
Most of the our products are subject to stringent government regulation
in the United States and other countries. These laws and regulations govern
product testing, manufacture, labeling, storage, record-keeping, distribution,
sale, marketing, advertising and promotion. The regulatory process can be
lengthy, expensive and uncertain, and securing clearances or approvals often
requires the submission of extensive official data and other supporting
information. If we don't comply with regulatory requirements, we may be subject
to fines, recall or seizure of products, total or partial suspension of
production, withdrawal of existing product approvals or clearances, refusal to
approve or clear new applications or notices and criminal prosecution. Further,
any change in existing federal, state or foreign laws or regulations, or in
their interpretation or enforcement, or the enactment of any additional laws or
regulations, could affect us both materially and adversely.
In the United States, the FDA regulates medical devices under the Food,
Drug, and Cosmetic Act (the "FDC Act"). Before a new medical device can be
commercially introduced in the United States, the manufacturer usually must
obtain FDA clearance by filing a pre-market notification under Section 510(k) of
the FDC Act (a "510(k) Notification") or obtain FDA approval by filing a
pre-market approval application (a "PMA Application"). The PMA Application
process is significantly more complex, expensive, time-consuming and uncertain
than the 510(k) Notification process. To date, we have cleared all of our
regulated products with the FDA through the 510(k) Notification process. Of
course, we can't guarantee that we will be able to use the 510(k) Notification
process for future products. Furthermore, FDA clearance of a 510(k) Notification
or approval of a PMA Application is subject to continual review, and the
subsequent discovery of previously unknown facts may result in restrictions on a
product's marketing or withdrawal of the product from the market.
We are also required to register as a medical device manufacturer with
the FDA and comply with FDA regulations concerning good manufacturing practices
for medical devices ("GMP Standards"). In 1997, the FDA expanded the scope of
the GMP Standards with new regulations requiring medical device manufacturers to
maintain control procedures for the design process, component purchases and
instrument servicing. The FDA periodically inspects our manufacturing facilities
for compliance with GMP Standards. We believe that we are in substantial
compliance with the expanded GMP Standards.
7
10
The FDA also regulates computer software of the type used in The Yellow
IRIS and is currently reevaluating the regulation of such software. We can't
predict the extent to which the FDA will regulate such software in the future.
Labeling, advertising and promotional activities for medical devices are
subject to scrutiny by the FDA and, in certain instances, by the Federal Trade
Commission. The FDA also enforces statutory and policy prohibitions against
promoting or marketing medical devices for unapproved uses.
Many states have also enacted statutory provisions regulating medical
devices. The State of California's requirements in this area, in particular, are
extensive, and require registration with the state and compliance with
regulations similar to the GMP Standards established by the FDA. While the
impact of such laws and regulations has not been significant to date, it is
possible that future developments in this area could affect us both materially
and adversely.
In addition to domestic regulation of medical devices, many of our
products are subject to regulations in foreign jurisdictions. The requirements
for the sale of medical devices in foreign markets vary widely from country to
country, ranging from simple product registrations to detailed submissions
similar to those required by the FDA. We have not yet applied for regulatory
clearances or approvals to market The Yellow IRIS in most of these foreign
countries. Our business strategy includes expanding the geographic distribution
of these and other products, and we cannot guarantee that we will be able to
secure the necessary clearances and approvals in the relevant foreign
jurisdictions. Furthermore, the regulations in certain foreign jurisdictions
continue to develop and we cannot be sure that new laws or regulations will not
have a material adverse effect on our existing business or future plans. Among
other things, CE Mark certifications are, or may soon be, required for the sale
of many products in certain international markets such as the European
Community. We do not plan to pursue CE Mark certification for The Yellow IRIS
until we have completed our new platform, and this may hinder foreign sales of
The Yellow IRIS in the interim.
Our products are also subject to regulation by the United States
Department of Commerce export controls, primarily as they relate to the
associated computers and peripherals. We have not experienced any material
difficulties in obtaining necessary export licenses to date.
SEGMENT AND GEOGRAPHIC INFORMATION
See Note 17 to the Consolidated Financial Statements, "Segment and
Geographic Information," for financial information regarding our operating
segments and geographic areas.
EMPLOYEES
At December 31, 1999, we had 143 full-time employees, which is
comparable to the number of employees at the end of 1998. Of this number, 39
people were employed by Perceptive Scientific Instruments, a business we plan to
sell. Please see "Management's Discussion and Analysis-Discontinued Business
Operations" on p. 17 for a discussion of these plans. We also use outside
consultants and part-time and temporary employees in production, administration,
marketing and engineering. No employees are covered by collective bargaining
agreements, and we believe that our employee relations are satisfactory.
GLOSSARY OF SELECTED TERMS
The following glossary defines certain technical terms used to describe
the Company's business.
AUTOMATED INTELLIGENT MICROSCOPY (AIM). The synthesis of visual
microscopy, digital image processing and automated image interpretation/pattern
recognition to analyze microscopic specimens. The Yellow IRIS, The White IRIS
and PowerGene are all examples of instruments which are based on AIM technology.
AUTOMATIC KARYOTYPING. A procedure to capture and digitize an image of a
spread of chromosomes from a dividing nucleus (metaphase) which may be further
enhanced by image processing. The individual chromosomes
8
11
in the enhanced image are then automatically separated, matched and aligned into
their respective pairs (karyotype).
COMPARATIVE GENOMIC HYBRIDIZATION(CGH). A molecular biology method to
globally view DNA for gain or loss (amplifications or deletions) of genetic
material using a FISH procedure.
CYTOPROBE. A chemical reagent which reacts with enzymatic granules
within a cell to produce unique color characteristics which are useful in
identifying the cell.
DNA. Deoxyribonucleic acid, the chemical composition of chromosomes in
the nuclei of living cells, consisting of two long chains of alternating
phosphate and deoxyribose units twisted into a double helix and joined by
hydrogen bonds between the complementary bases adenine and thymine or cytosine
and guanine bound in unique sequences that determine genetic characteristics.
DNA PROBE ANALYSIS. A molecular biology method using synthesized nucleic
acid comprised of unique short sequences of DNA (deoxyribonucleotides) to locate
their exact template along the DNA chain in the nucleus of a cell.
FLUORESCENT IN-SITU HYBRIDIZATION (FISH). A procedure that allows
microscopic observation of the location of a unique sequence of DNA by using a
DNA probe with a molecule attached to it which emits a distinctive color when
illuminated.
IN VITRO DIAGNOSTIC (IVD) TESTING. Testing conducted outside of the body
in a laboratory apparatus using a specimen obtained from the patient (blood,
urine, tissue, etc.) to identify or monitor a disease.
MULTIPLEX FLUORESCENT IN-SITU HYBRIDICATION (M-FISH). A procedure which
utilizes a multiple combination of unique sequence DNA probes and fluorescent
markers to label all 22 chromosome pairs and 2 sex chromosomes in 24 unique
colors, permitting easy and rapid identification of chromosomal breakage and
rearrangements (translocations) such as often observed in cancer cells.
REFERENCE LABORATORY. A commercial clinical laboratory which performs
general IVD testing of specimens referred from physician offices and more
specialized IVD testing for physician offices and hospitals.
REFRACTOMETER. A device which measures the index of refraction of a
solution, typically to determine its concentration or specific gravity.
SLIDELESS MICROSCOPY. The process of presenting a microscopic specimen
to the optical portion of a microscope without using a conventional microscope
slide. Slideless microscopy is implemented in The Yellow IRIS and The White IRIS
using a patented flowcell through which the specimen literally flows past a
microscope objective.
ITEM 2. PROPERTIES
We lease all of our facilities. The leases expire at various times over
the next three years. Our headquarters are located at 9162 Eton Avenue,
Chatsworth, California 91311. The table below sets forth certain information
regarding our leaseholds as of December 31, 1999:
9
12
Approximate Floor- Monthly
Location Space (Sq. Ft.) Rent Use
- -------- ---------------- ---- ---
Chatsworth, CA 26,000 $14,600 Sales and Marketing, Research and Development,
Manufacturing and Corporate Administration
Norwood, MA 11,000 $ 7,800 Sales and Marketing, Research and Development and
Manufacturing
We believe our facilities are adequate to meet our current needs.
Although we have limited expansion space at our Chatsworth facility, we believe
we can accommodate planned growth at this facility for the near term by leasing
additional office space for certain non-manufacturing related activities, making
modifications to the Chatsworth facility and adding a second shift to our
manufacturing operations.
ITEM 3. LEGAL PROCEEDINGS
In October 1999, we were awarded $132,500 from the arbitration against
Digital Imaging Technologies, Inc. (DITI), the former owner of our Perceptive
Scientific Instruments genetic analysis business. The arbitration was conducted
under the auspices of the American Arbitration Association. The arbitration
panel found that while certain representations, warranties and covenants in the
purchase agreement for the transaction had been breached by DITI, these breaches
did not damage us significantly. See "Legal Proceedings" in the our Quarterly
Report on Form 10-Q for the quarter ended June 30, 1999 for historical
information on the arbitration.
We are involved in routine litigation arising in the ordinary course of
our business, and, while we cannot predict the outcome of these proceedings, we
believe they will not materially or adversely affect us.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
We did not submit any matters to vote of security holders during the
quarter ended December 31, 1999.
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS
IRIS Common Stock is traded on the American Stock Exchange under the
symbol "IRI." The closing price of the Common Stock on March 15, 2000 was
$2-13/16 per share. The table below sets forth high and low closing prices
reported by American Stock Exchange for the period January 1, 1998 through
December 31, 1999:
Price per share
-------------------
High Low
---- ---
FISCAL 1998
First Quarter ....... $4-11/16 $3-1/4
Second Quarter ...... 4-1/8 2
Third Quarter ....... 2-3/8 1-1/16
Fourth Quarter ...... 1-1/2 3/4
FISCAL 1999
First Quarter ....... $1-1/8 $11/16
Second Quarter ...... 1-1/2 9/16
Third Quarter ....... 1-1/4 15/16
Fourth Quarter ...... 1-3/16 9/16
As of March 15, 2000, we had approximately 4,100 holders of record of
our common stock.
10
13
We intend to use all available funds in business development and debt
repayment. As a result, we do not expect to pay any cash dividends for the
foreseeable future. Furthermore, we may not pay any cash dividends on the Common
Stock, or repurchase any shares of the Common Stock, without the written consent
of our lender, Foothill Capital Corporation, and the holders of a majority of
the outstanding shares of Series B Preferred Stock.
ITEM 6. SELECTED FINANCIAL DATA
This information as of December 31, 1998 and 1999 and for the years
ended December 31, 1997, 1998 and 1999, is derived in part from, and should be
read in conjunction with Management's Discussion and Analysis and the Company's
Financial Statements, including the Notes thereto, included elsewhere in this
Annual Report.
Year Ended December 31,
----------------------------------------------------------------
1995(1) 1996(1) 1997(1) 1998(1) 1999(1)
-------- -------- -------- -------- --------
FINANCIAL STATEMENT DATA (in thousands, except per share data)
Net revenue ................................. $ 14,488 $ 18,130 $ 20,724 $ 21,581 $ 25,725
Operating income (loss) from continuing
operations ................................ (1,802) (2,419) 1,007 2,202 390
Interest and other income (expense), net .... 282 (437) (1,099) (1,115) (947)
Income (loss) from continuing operations .... 2,126 (2,441) (58) 667 (1,088)
Income (loss) from continuing operations
per share - basic ......................... .35 (.40) (.01) .11 (.15)
Income (loss) from continuing operations
per share - diluted ....................... .34 (.40) (.01) .09 (.15)
Working capital ............................. 11,234 1,914 1,650 3,570 5,092
Total assets ................................ 22,203 37,860 32,735 32,107 26,661
Long term debt, including current portion ... 311 13,000 10,942 10,442 8,700
Total liabilities ........................... 3,261 24,096 17,942 17,108 16,439
Shareholders' equity ........................ 18,942 13,765 14,792 14,999 10,222
Other Financial Data
Operating income (loss) from continuing
operations as adjusted(2) ................. 1,098 (560) 2,346 2,395 4,549
- -------------
(1) The year ended December 31, 1995 includes write-offs of acquired in
process research and development totaling $2.9 million. The year ended
December 31, 1996 also includes unusual charges totaling $1.9 million
relating primarily to pooling-of-interest expenses, the write-off of
deferred public offering costs, expenses relating to litigation and
arbitration matters, severance and other incremental costs associated
with a restructuring of the Company's personnel. The year ended December
31, 1997 includes unusual charges totaling $1.3 million relating to
expenses for litigation and assets related to the White IRIS leukocyte
differential analyzer program, the write-off of deferred private
offering costs and the write-off of goodwill no longer considered
recoverable. The year ended December 31, 1998 includes unusual charges
totaling $193,000 primarily for legal expenses associated with an
arbitration matter. Unusual charges in the year ended December 31, 1999
totaled $4.2 million and primarily relate to a litigation settlement,
write-off of assets related to the White IRIS leukocyte differential
analyzer program and a retirement agreement.
(2) Operating income (loss) from continuing operations as adjusted
represents operating income (loss) from continuing operations before the
write-off of acquired in-process research and development totaling $2.9
million in the year ended December 31, 1995 and before unusual charges
of $1.9 million, $1.3 million, $193,000 and $4.2 million in the years
ended December 31, 1996, 1997, 1998 and 1999, respectively.
11
14
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
INTRODUCTION
In March of 2000, we entered into a letter of intent to sell
Perceptive Scientific Instruments, our genetic analysis business. In light of
our plans to sell Perceptive Scientific Instruments, we are treating this
business as a discontinued operation for accounting purposes, and we have
removed it from most of the discussion and financial information in this Annual
Report. For a further discussion of our plans to sell this business, please see
the section below on page 17 entitled "Discontinued Business Operations."
OVERVIEW
We generate revenues primarily from sales of The Yellow IRIS urinalysis
workstation, an IVD imaging system based on our patented and proprietary AIM
technology, and the related supplies and service required to operate this
workstation. We also earn revenues from sales of ancillary lines of small
laboratory instruments and supplies.
Until 1996, we marketed just two models of The Yellow IRIS urinalysis
workstation. These models differ mainly in speed and price. In 1996, we
introduced a third model of The Yellow IRIS, the Model 900UDx urine pathology
system. This model is a higher capacity automated urinalysis workstation
designed especially for the high-volume testing requirements of large hospitals
and reference laboratories.
In December 1997, we began distributing the IRIS/Sysmex UF-100 urine
cell analyzer in the United States under an exclusive agreement with its
manufacturer, Sysmex Corporation. We did not have significant sales of the
UF-100 in 1998 or 1999. In September 1998, Sysmex started procedures to end the
exclusive nature of our distribution rights, claiming inadequate sales
performance. We denied these allegations. Sysmex has announced that its U.S.
subsidiary will distribute the UF-100 in North America. We may take legal
action. We cannot predict the impact on the Company of this announcement or any
legal action we may take.
Because of the nature of our business, we make significant investments
in research and development for new products and enhancements to existing
products. In the past, we have partially funded our research and development
programs through grants from the National Institutes of Health, joint
development programs with strategic partners and Company-sponsored research and
development entities. We anticipate that future expenditures on research and
development will increase significantly and will be funded entirely out of the
Company's earnings. See "Business -- Research and Development."
The following table summarizes total product technology expenditures for
the periods indicated:
Year Ended December 31,
---------------------------------
1997 1998 1999
------ ------ -------
(in thousands)
Research and development expense, net ................................ $1,600 $1,879 $ 1,124
Capitalized software development costs ............................... 366 179 248
Reimbursed costs for research and development grants and contracts ... 517 140 (3)
------ ------ -------
Total product technology expenditures ....................... $2,483 $2,198 $ 1,369
====== ====== =======
In 1995, we entered into a joint development project with Poly U/A
Systems, Inc. for development of several new products to enhance automated
urinalysis. Subsequently, certain disputes arose with the Poly U/A shareholders.
In 1999, we made a tender offer to acquire all of the outstanding shares of
Poly U/A stock for a package of IRIS securities with an estimated value of up to
$1.5 million. Approximately 79% of the outstanding shares of Poly U/A were
tendered in this transaction. We have recorded the cost of purchasing Poly U/A
stock as a litigation settlement expense. Poly U/A is now a majority-owned
subsidiary of IRIS, and is accounted for accordingly.
12
15
RESULTS OF OPERATIONS
COMPARISON OF YEAR ENDED DECEMBER 31, 1999 TO YEAR ENDED DECEMBER 31,
1998
Net revenues for the year ended December 31, 1999 increased to $25.7
million from $21.6 million, an increase of $4.1 million, or 19%, over last year.
Sales of IVD imaging systems increased to $6.5 million from $5.0 million, an
increase of $1.5 million, or 30% from the last year. The increase is due
primarily to higher sales to both domestic hospitals and international
distributors. Sales of IVD imaging system supplies and services increased to
$13.6 million from $11.8 million, an increase of $1.8 million or 15% over last
year, primarily due to the larger installed base of The Yellow IRIS IVD imaging
systems. Sales of small instruments and supplies increased to $5.3 million from
$4.3 million, an increase of $952,000, or 22%.
Revenues from the urinalysis segment totaled $20.4 million in the
current period as compared to $17.0 million last year, an increase of $3.4
million or 20%. This growth is due to increased sales of The Yellow IRIS family
of workstations and increased sales of related system supplies and services to
the growing installed base. Revenues from small laboratory devices segment
increased to $5.3 million in the current period, as compared to $4.6 million
last year, an increase of $717,000. If the non-recurring royalty fee earned from
the prior year is excluded, small laboratory device sales increased $952,000.
This growth is primarily due to increased sales of instruments and consumables
to a larger installed base and one of its distributors.
Cost of goods for IVD systems as a percentage of sales of IVD imaging
systems totaled 66% in the current period and is comparable to last year. An
increase in proportion of sales of The Yellow IRIS urinalysis workstation to
international distributors with associated lower margins and high costs
associated with the write-off of The White IRIS inventory were offset by lower
costs associated with domestic sales. Cost of goods for IVD imaging system
supplies and services as a percentage of sales of such products decreased to 44%
for the current period as compared to 46% for the same period last year. This
decrease is due to increased revenues while related expenses decreased. Cost of
goods for small instruments and supplies as a percentage of sales of small
instruments and supplies totaled 52% for the current year compared to 55% for
last year due to a change in the sales mix and increased volume. The aggregate
gross margin totaled 49% for the year ended December 31, 1999, and is comparable
to last year's.
Cost of goods sold as a percentage of revenues from the urinalysis
segment totaled 50%, as compared to 68% last year. This decrease results from
increased urinalysis supplies and services revenues along with lower associated
expenses, partially offset by lower margins on system sales and the write-off of
The White IRIS inventory. Cost of goods for small instrument devices segment as
a percentage of revenues totaled 52% in the current period, and is comparable to
last year. If the nonrecurring royalty fee is excluded, cost of goods sold as a
percentage of sales for this segment declined 3% in 1999.
Marketing and selling expenses totaled $3.3 million, compared to $3.2
million last year, an increase of $72,000, or 2%, due to increased promotional
activities associated with The Yellow IRIS urinalysis workstation. Marketing and
selling expenses as a percentage of net revenues declined to 13% in 1999 as
compared to 15% last year.
General and administrative expenses increased to $3.5 million from $2.7
million, an increase of $744,000 or 27% from last year. This increase is
primarily due to higher liability insurance, management incentives and increased
expenses associated with the Office of the Chief Executive and the Board of
Directors. General and administrative expenses as a percentage of net revenues
totaled 13%, and is comparable to last year.
Net research and development expenses decreased to $1.1 million for the
year ended December 31, 1999, as compared to $1.9 million in 1998. Net research
and development expenses decreased as a percentage of revenues from 9% to 4%.
Reimbursements under joint development programs decreased by $143,000 from the
prior year. Total product technology expenditures, including capitalized
software development costs and reimbursed costs under research and development
grants and contracts, decreased to $1.4 million from $2.2 million, a decrease of
$829,000 or 38% as compared to last year. The decline in total product
technology expenditures is due to decreased spending on The Yellow IRIS family
of products.
We began a major project in 1999 to improve The Yellow IRIS urinalysis
workstation product line. As a result, we expect significant increases in our
net research and development expenses above 1999 levels. We have completed
feasibility studies on the proposed improvements. We believe that this project
is important to maintaining our competitive position in the urinalysis market
and that our failure to successfully complete this project on schedule could
have a material and adverse effect on future system sales.
13
16
Amortization of intangible assets reflects the amortization of deferred
expenses for warrants issued in connection with a joint development project,
intangible assets arising from an acquisition and patents. Amortization of,
intangible assets for the year ended December 31, 1999 decreased to $231,000
from $278,000, a decrease of $47,000, or 17%, from the prior year. The decline
is the result of the write-off in the third quarter of 1999 of the deferred
warrant costs for technology rights.
The results of operations for the year ended December 31, 1999 include
unusual expenses of $4.2 million as compared to $193,000 in the prior year. The
increase primarily relates to the write-off of deferred warrant costs
($807,000), write-off of the deferred software development costs associated with
The White IRIS ($797,000), settlement with Poly U/A ($1.7 million), legal and
other expenses relating to the recently completed DITI arbitration totaled
($392,000) net of recovery of $132,000 and expenses in connection with a
retirement agreement ($444,000). The prior year's expenses related to the DITI
arbitration.
The net result of the above described changes is an operating income of
$390,000 for the year ended December 31, 1999 as compared to an operating income
of $2.2 million in the same period last year. Excluding the litigation
settlement and other unusual charges and the write-off of The White IRIS,
operating income totaled $4.5 million for 1999 as compared to $2.4 million for
last year.
Interest expense decreased to $966,000 in 1999 from $1.2 million for
last year due to reduced indebtedness, partially offset by the effect of
increased interest rates on the credit facility.
For the year ended December 31, 1999, urinalysis segment profits
increased to $3.7 million as compared to $2.9 million last year. Excluding the
write-off of The White IRIS inventory and software development costs ($926,000)
and the deferred warrants costs ($807,000), the urinalysis segment profits would
have totaled $5.4 million. This increase is attributable to higher revenues
described above and lower operating expenses. Segment profits from the small
laboratory devices segment totaled $1.4 million, as compared to $1.1 million
last year. If the nonrecurring license fee earned in the prior year were
excluded, this segment's profit for last year totaled $844,000 as compared to
this year's $1.4 million. The increase results from increased product sales and
gross profits. Unallocated corporate expenses totaled $5.6 million in the
current period as compared to $2.9 million last year. The increase is due
primarily to the recently completed arbitration with DITI, the settlement with
Poly U/A and expenses associated with the Office of the Chief Executive and
Board of Directors and a retirement agreement.
The income tax provision for the year ended December 31, 1999 totaled
$531,000, as compared to a provision of $420,000 for 1998. The provision for
1999 includes $649,000 relating to an increase in the deferred tax valuation
allowance as a result of management's assessment of operating results, net
operating losses expected to expire in the near term, and other factors.
The above factors contributed to a loss from continuing operations of
$1,088,000 or $0.15 per share for the year ended December 31, 1999 as compared
to income from continuing operations of $667,000 or $0.09 per share for the
prior year. Excluding the unusual expenses and the write-off of The White IRIS
inventory, related tax benefits and the increase of the deferred income taxes
valuation allowance, the Company would have had net income from continuing
operations of $2.3 million or $0.30 per diluted share in 1999 and net loss of
$789,000, or $0.10 per share in the prior year.
COMPARISON OF YEAR ENDED DECEMBER 31, 1998 TO YEAR ENDED DECEMBER 31,
1997
Net revenues for the year ended December 31, 1998 increased to $21.6
million from $20.7 million, an increase of $857,000, or 4%, over last year.
Revenues from sales of urinalysis systems decreased to $5.0 million from $5.6
million, a decrease of $627,000, or 11%. The decrease is due to a decline in
domestic sales, partially offset by increased sales to an international
distributor. Sales of IVD system supplies and services increased to $11.8
million from $10.1 million, an increase of $1.7 million or 17% over the
comparable period last year, primarily due to the larger installed base of The
Yellow IRIS IVD imaging systems. Sales of small instruments and supplies
decreased to $4.3 million from $4.4 million, a decrease of $102,000.
Royalty and licensing revenue decreased to $465,000 for the year ended
December 31, 1998 as compared to
14
17
$603,000 in the prior year. The decrease is primarily due to differences in
non-recurring licensing fees received in the two years.
Revenues from the urinalysis segment totaled $17.0 million for the year
ended December 31, 1998 as compared to $16.2 million in the prior year, an
increase of $816,000. The net increase is due to increased revenues from
supplies and service for The Yellow IRIS which more than offset a decline in
sales of The Yellow IRIS instruments and a decline in licensing revenues.
Revenues from the small laboratory devices segment were essentially comparable
as increased licensing revenues were substantially offset by reduced purchases
by a major distributor.
Cost of goods for IVD systems increased as a percentage of their sales
to 66% for the year ended December 31, 1998 from 60% for the prior year. The
increase is primarily due to lower average selling prices of The Yellow IRIS
urinalysis workstations caused by an increased proportion of international
sales. Cost of goods for IVD system supplies and services as a percentage of
sales of such products decreased to 46% for the current period as compared to
49% for the prior year. The decrease is primarily due to decreased costs and
increased selling prices. Cost of goods for small instruments and supplies as a
percentage of sales of small instruments and supplies totaled 55% for 1998
compared to 53% for the prior year. The increase is primarily due to a change in
the sales mix. The net result of these changes resulted in an aggregate gross
margin to 49% for 1998, which is comparable to the prior year.
Cost of goods sold as a percentage of revenues from the urinalysis
segment totaled 68% in 1998, as compared to 51% in 1997. Lower average selling
prices for The Yellow IRIS workstation to an international distributor were
partially offset by improved pricing and decreased costs on supplies and
service. Cost of goods for the small instrument devices segment as a percentage
of revenues totaled 52% in 1998 and 1997.
Marketing and selling expenses consist primarily of salaries,
commissions and related travel expenses of the Company's direct sales force, as
well as salaries for the marketing and distributor relations departments.
Marketing and selling expenses totaled $3.2 million for the year ended December
31, 1998, and is comparable to the prior year. Marketing and selling expenses as
a percentage of net revenues amounted to 15% in 1998 and 1997.
General and administrative expenses consist primarily of payroll costs
associated with the Company's management and support personnel, facilities
related costs and legal and accounting fees. General and administrative expenses
increased to $2.7 million for the year ended December 31, 1998 from $2.6
million, an increase of $122,000 or 5% over the prior year, primarily due to
additional executive positions, severance charges and charges associated with
the repricing of options held by consultants. These increases were partially
offset by lower legal and accounting expenses. General and administrative
expenses as a percentage of net revenues totaled 13% in 1998 and 1997.
Net research and development expenses consist of costs incurred for the
development of new products and improvements to existing products less
third-party reimbursements under joint development programs, grants and research
and development contracts. Net research and development expenses increased to
$1.9 million for the year ended December 31, 1998 from $1.6 million in the prior
year, an increase of $279,000 or 17%, due to increased expenditures and
decreased external funding under joint development programs. Net research and
development expenses as a percentage of net revenues amounted to 9% in 1998 and
8% in 1997. Reimbursements under joint development programs decreased to
$140,000 from $517,000. Total product technology expenditures, including
capitalized software development costs and reimbursed costs under research and
development grants and contracts, totaled to $2.2 million, as compared to $2.5
million the prior year.
Amortization of intangible assets reflects the amortization of deferred
expenses for warrants issued in connection with joint development projects and
intangible assets arising from acquisitions and patents. Amortization of
intangible assets for the year ended December 31, 1998 decreased to $278,000
from $426,000, a decrease of $148,000 or 35% from the prior period. The decline
is primarily the result of the write-off in the fourth quarter of 1997 of
goodwill from the digital refractometer product line acquired in 1995.
The results of operations for the year ended December 31, 1998 include
unusual charges of $193,000 relating primarily to legal expenses for a pending
arbitration matter. See "Legal Proceedings." The unusual charges in the
15
18
prior year totaled $1.3 million and related primarily to the write-off of
deferred private offering expenses, goodwill no longer considered recoverable
associated with the digital refractometer product line and legal expenses.
The net result of the above-described changes was an increase in
operating income to $2.2 million in 1998, as compared to $1.0 million in the
prior year. For the year ended December 31, 1998, urinalysis segment profits
increased to $2.9 million as compared to $2.7 million in the prior year, an
increase of $147,000 or 5%. This increase is largely attributable to increased
sales of related supplies and service described above, partially offset by a
small increase in operating expenses and lower system margins. Segment profits
from the small laboratory devices segment totaled $1.1 million in 1998 as
compared to $372,000 in 1997. The improvement is due to the increase in this
segment's licensing revenues and the write-off in 1997 of goodwill associated
with the digital refractometer product line. Unallocated corporate expenses
totaled $2.9 million in 1998 as compared to $3.2 million in the prior year, a
decrease of $325,000. This is due to decreased unusual charges for deferred
offering costs and legal expenses as described above.
The income tax provision for the year ended December 31, 1998 totaled
$420,000 as compared to an income tax benefit of $34,000 for 1997. The income
tax benefit for the year ended December 31, 1998 differs from the federal
statutory rate due to state, local and foreign income taxes and permanent
differences between income reported for financial statement and income tax
purposes.
The above factors contributed to income from continuing operations of
$667,000 or $0.09 per diluted share for the year ended December 31, 1998 as
compared to a net loss of $58,000 or $0.01 per diluted share for the year ended
December 31, 1997.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents increased to $2.0 million at December 31, 1999
from $389,000 at December 31, 1998. The increase is due to the cash provided by
operations in excess of amounts used by investing and financing activities. Cash
provided by operations for the year ended December 31, 1999 increased to $3.8
million from $960,000 for the comparable period last year. This increase is
primarily due to the decrease in inventory levels, improved operations
(excluding unusual noncash write-offs) and increased accrued liabilities.
Cash used by investing activities totaled $681,000 for the year ended
December 31, 1999, as compared to $1.2 million in the prior year. The decrease
is primarily due to the decline in expenditures for property and equipment,
offset by the proceeds from the sale of The Yellow IRIS urinalysis workstations
previously subject to an operating lease.
The credit facility with Foothill Capital Corporation, a Wells Fargo
company, consists of a $3.6 million term loan and a $4.0 million revolving line
of credit. Borrowings under the line of credit are limited to a percentage of
eligible accounts receivable and are subject to a combined limit of $7.0 million
for the total credit facility. The term loan bears interest at the lender's
prime rate (8.5% on December 31, 1999) plus 3.0%, and is payable in 36 equal
monthly installments. The revolving line of credit bears interest at the
lender's prime rate plus 1.0%. The credit facility is subject to minimum
interest charges, prepayment penalties and customary fees, is collateralized by
a first priority lien on all the assets of the Company and matures in 2001. It
also contains financial covenants based primarily on tangible net worth and cash
flow and imposes restrictions on acquisitions, capital expenditures and cash
dividends. We were not in compliance with one of these financial covenants at
year end, and the credit facility has been amended to waive the non-compliance
and modify the financial covenants for future periods.
16
19
We began a major project in 1999 to improve The Yellow Iris urinalysis
workstation product line. As a result, we expect significant increases in our
research and development expenditures. We plan to fund this project with cash
from operations.
Net cash used by financing activities totaled $1.5 million and consisted
primarily of principal payments made on the term loan described above and notes
payable due to Corange International Limited, an affiliate of the Boehringer
Mannheim group of companies, partially offset by net proceeds from
borrowings on the revolving line of credit. As of December 31, 1999, $1.7
million was outstanding under the term loan and $655,000 was outstanding under
the revolving line of credit; $2.0 million remained available for future
borrowings under the revolving credit line.
We reduced our outstanding debt by $1.8 million in 1999 and we have
scheduled principal payments totaling $1.2 million during the next twelve
months. We believe that our current cash on hand, together with cash generated
from operations and cash available under the credit facility, will be sufficient
to fund normal operations and pay principal and interest on outstanding debt
obligations for the next 19 months. On July 31, 2001, our $7.0 million
subordinated note becomes due and payable. We anticipate that we will have to
seek proceeds from a debt or equity financing in order to meet this obligation.
We issued 198,000 shares of Series B Callable Preferred Stock in
connection with the tender offer for Poly U/A. See "--Overview." These shares
have a liquidation preference of $3 per share (or an aggregate liquidation
preference of $594,000). The "callable" feature entitles us to convert the
preferred stock at any time into a number of shares of common stock equal to the
liquidation value divided by the market price of the common stock at the time of
conversion (subject to a minimum value of $2.00 per share of common stock). The
preferred stock will automatically convert under the same formula on August 3,
2002 if we have not converted it sooner. Based on the average closing price of
$0.76 for the five-day period ending December 31, 1999, the call price would be
the $2.00 minimum, and we could convert the Series B Callable Preferred Stock
into 297,000 shares of common stock. The Series B Callable Preferred Stock is
non-voting, is not entitled to any preferred dividends, and is not subject to
any mandatory or optional redemption provisions. We are not permitted to pay
cash dividends on our common stock or to repurchase any shares of our common
stock without the written consent of the holders of a majority of the Series B
Callable Preferred Stock.
DISCONTINUED BUSINESS OPERATIONS
We acquired Perceptive Scientific Instruments in July 1996. Its
principal product line is the PowerGene family of genetic analyzers -- IVD
imaging systems for karyotyping, DNA probe analysis and comparative genomic
hybridization. In March of 2000, we entered into a letter of intent to sell
this business to a well-known international company for an estimated price of
$2.5 to $5.0 million in cash. The exact price depends on the results of the
buyer's remaining due diligence and the satisfaction of certain conditions. The
most significant condition is the successful transfer of certain government
research contracts to the buyer, and this may require governmental approval.
In light of our plans to sell Perceptive Scientific Instruments, we are
treating this business as a discontinued operation for accounting purposes, and
we have removed it from most of the discussion and financial information and in
this Annual Report to reflect this treatment. However, the letter of intent is
not a binding agreement, and we cannot be sure that this transaction will occur.
Closing this transaction depends upon the outcome of the buyer's remaining due
diligence, the satisfaction of various conditions set by the buyer, negotiating
and signing a definitive written sale agreement and board of director approval
from both companies. If this sale does not occur, we plan to pursue other
opportunities for a disposition of this business.
SHAREHOLDER RIGHTS PLAN
We adopted a shareholders rights plan in December 1999. The rights are
not presently exercisable. They become exercisable only if a person or group
acquires 20% or more of our common stock, or announces a tender offer for 20%
or more of our common stock, without board approval. If the rights are
triggered, all common stockholders (except the hostile party) will be entitled
to purchase shares of common stock (or the economic equivalent in preferred
stock) at a price based on a substantial discount from the market price of the
common stock. The Board of Directors may terminate the plan at any time or
redeem the rights prior to their becoming exercisable. The rights expire on
December 22, 2009.
NET OPERATING LOSS CARRYFORWARDS
At December 31, 1999, we had federal net operating loss carryforwards of
approximately $17.5 million. If substantially all of our outstanding options and
warrants, including the warrants issued in the Poly/UA transaction, are
exercised on or before December 31, 1999, these transactions in combination with
other prior stock issuances during the past three years would constitute a
"change of ownership" under Section 382 of the Internal Revenue
17
20
Code. Section 382 imposes an annual limitation on the utilization of net
operating loss carryforwards based on a statutory rate of return (usually the
applicable federal rate) and the value of the corporation at the time of the
change of ownership. Depending on the market price of our common stock at the
time a change of ownership occurs, the resulting limitations imposed by Section
382 could trigger a substantial write down in our deferred tax assets and a
corresponding charge to earnings in the relevant quarter.
YEAR 2000 PROBLEM
The Year 2000, or Y2K, problem arose because many existing computer
programs use only the last two digits to recognize a year. This issue has not
had a material adverse effect on our operations.
MARKET RISK
Our business is exposed to various market risks, including changes in
interest rates and foreign currency exchange rates. Market risk is the potential
loss arising from adverse changes in market rates and prices, such as interest
rates and foreign currency exchange rates. We do not enter into derivatives or
other financial instruments for trading or speculative purposes.
Interest Rates
We rely significantly on long- and short-term fixed and variable rate
debt in our capital structure. We do not use interest rate swaps to manage any
of our floating-rate debt obligations. As of December 31, 1999, our debt
obligations consisted of (1) $7.0 million outstanding under an 8.5% fixed rate
subordinated note, (2) $1.7 million outstanding under a variable rate term loan
and (3) $655,000 outstanding under a variable rate revolving line of credit. The
variable rate obligations are based upon the lender's prime rate. See "--
Liquidity and Capital Resources." Assuming an increase of one-half of a
percentage point in the lender's prime rate on January 1, 2000 and no principal
payments for the remainder of the year, our total interest expense would
increase by less than $100,000 for 2000 as compared to 1999.
Foreign Currencies
We are subject to some currency risk on a portion of our licensing
revenues. This portion is calculated quarterly based on sales results in
Japanese Yen and subsequently converted into United States dollars at the then
current exchange rate.
INFLATION
We do not foresee any material impact on our operations from inflation.
HEALTHCARE REFORM POLICIES
In recent years, an increasing number of legislative proposals have been
introduced or proposed in Congress and in some state legislatures that would
effect major changes in the healthcare system, nationally, at the state level or
both. Future legislation, regulation or payment policies of Medicare, Medicaid,
private health insurance plans, health maintenance organizations and other
third-party payors could adversely affect the demand for our current or future
products and our ability to sell our products on a profitable basis. Moreover,
healthcare legislation is an area of extensive and dynamic change, and we cannot
predict future legislative changes in the healthcare field or their impact on
our business.
18
21
FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements
which reflect our current views about future events and financial results. We
have made these statements in reliance on the safe harbor created by that
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include our views on future financial results, financing sources, product
development, capital requirements, market growth and the like, and are generally
identified by phrases such as "anticipates," "believes," "estimates," "expects,"
"intends," "plans" and similar words. Forward-looking statements are merely
predictions and therefore inherently subject to uncertainties and other factors
which could cause the actual results to differ materially from the
forward-looking statement. These uncertainties and other factors include, among
other things,
- our ability to secure additional financing to repay the
remaining principal balance of our long-term debt and to fund
our long-term business strategy,
- unexpected technical and marketing difficulties inherent in
major product development efforts such as the new platform for
The Yellow IRIS,
- the potential need for changes in our long-term strategy in
response to future developments,
- future advances in diagnostic testing methods and procedures, as
well as potential changes in government regulations and
healthcare policies, both of which could adversely affect the
economics of the diagnostic testing procedures automated by our
products,
- rapid technological change in the microelectronics and software
industries, and
- increasing competition from imaging and non-imaging based
in-vitro diagnostic products.
We have attempted to identify additional significant uncertainties and
other factors affecting forward-looking statements in Exhibit 99 to this Annual
Report. Stockholders should understand that the uncertainties and other factors
identified in this Annual Report and in Exhibit 99 are not a comprehensive list
of all the uncertainties and other factors which may affect forward-looking
statements. We do not undertake any obligation to update or revise any
forward-looking statements or the list of uncertainties and other factors which
could affect those statements.
NEW ACCOUNTING PRONOUNCEMENTS
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements," which provides the SEC's views on applying generally accepted
accounting principles to selected revenue recognition issues. The Company is
presently evaluating the impact, if any, that this may have on the Company's
revenue recognition policies.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
See "Management's Discussion and Analysis of Financial Condition and
Results of Operations -- Market Risk."
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The financial statements are listed in the Index to Financial Statements
in Part IV, Item 14(a)1.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Incorporated by reference from "Directors and Executive Officers" in the
Proxy Statement to be filed with the Securities and Exchange Commission for the
2000 Annual Meeting of IRIS Stockholders.
ITEM 11. EXECUTIVE COMPENSATION
19
22
Incorporated by reference from "Executive Compensation" in the Proxy
Statement to be filed with the Securities and Exchange Commission for the 2000
Annual Meeting of IRIS Stockholders.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Incorporated by reference from "Security Ownership of Certain Beneficial
Owners and Management" in the Proxy Statement to be filed with the Securities
and Exchange Commission for the 2000 Annual Meeting of IRIS Stockholders.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Incorporated by reference from "Certain Relationships and Related
Transactions" in the Proxy Statement to be filed with the Securities and
Exchange Commission for the 2000 Annual Meeting of IRIS Stockholders.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) The following documents are filed as a part of this report:
Page
----
1. Index To Financial Statements
Report of Independent Public Accountants .................................... F-1
Consolidated Balance Sheets at December 31, 1999 and 1998 ................... F-2
Consolidated Statements of Operations for the Years
Ended December 31, 1999, 1998 and 1997 .............................. F-3
Consolidated Statements of Shareholders' Equity for the
Years Ended December 31, 1999, 1998 and 1997 ........................ F-5
Consolidated Statements of Cash Flows for the Years
Ended December 31, 1999, 1998 and 1997 .............................. F-8
Consolidated Statements of Comprehensive Income for the
Years Ended December 31, 1999, 1998 and 1997 ........................ F-9
Notes to Consolidated Financial Statements .................................. F-10
2. Financial Statement Schedules Covered by the Foregoing Report of Independent
Public Accountants
Schedule II -- Valuation and Qualifying Accounts .................... F-26
Other financial statement schedules have been omitted since they are not
required, are not applicable, or the required information is shown in the
Financial Statements or Related Notes.
3. Exhibits
Exhibit Reference
Number Description Document
- ------ ----------- --------
3.1(a) Certificate of Incorporation, as amended (1)
3.1(b) Certificate of Designations of Series A Convertible Preferred Stock (2)
3.1(c) Certificate of Designations of Series B Callable Preferred Stock (3)
3.1(d) Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
3.2 Restated Bylaws (5)
4.1 Specimen of Common Stock Certificate (6)
4.2 Certificate of Designations of Series A Convertible Preferred Stock (2)
4.3 Certificate of Designations of Series B Callable Preferred Stock (3)
4.4 Certificate of Designations, Preferences and Rights of Series C Preferred (4)
20
23
Stock
10.1 Lease of the Company's headquarters facility, as amended (7)
10.2(d) 1994 Stock Option Plan and forms of Stock Option Agreements (8)
10.2(e) Certificate of Officer With Respect to Amendment of 1994 Stock Option Plan (9)
10.2(f) Employee Stock Purchase Plan --
10.2(g) 1997 Stock Option Plan and form of Stock Option Agreement (10)
10.2(h) 1998 Stock Option Plan and form of Stock Option Agreement (11)
10.3(a) Various Agreements with Sysmex Corporation, formerly TOA Medical Electronics Company, Ltd. (12)
10.3(b) Patent License Agreement dated April 1, 1997 between the Company and Sysmex Corporation, (13)
formerly TOA Medical Electronics Company, Ltd.
10.3(c) Amendment No. 1 to Patent License Agreement dated February 29, 2000 --
10.3(d) Termination, Release and Reassignment of Security Interest dated October 30, 1997 executed by (13)
Sysmex Corporation, formerly TOA Medical Electronics Company, Ltd. in favor of the Company
10.4(a) Agreement for a Strategic Alliance in Urinalysis dated January 7, 1994 between the Company and (14)
Boehringer Mannheim Corporation
10.4(b) Amendment to Distribution Agreements (15)
10.5(a) Technology License Agreement dated as of September 29, 1995 between the Company and Poly U/A (16)
Systems, Inc.
10.5(b) Research and Development Agreement dated as of September 29, 1995 between the Company and Poly (16)
U/A Systems, Inc.
10.5(c) $100 Class "A" Note dated September 29, 1995 issued by Poly U/A Systems, Inc. in favor of the (16)
Company
10.5(d) Form of Series D Warrant (13)
10.5(g) Form of Series E Warrant (13)
10.6(a) Registration Rights and Standstill Agreement dated July 31, 1996 between the Company and (9)
Digital Imaging Technologies, Inc.
10.6(b) Restated Warrant Certificates dated July 31, 1996, originally issued in connection with the
acquisition of Perceptive Scientific Instruments, Inc., to purchase 875,000 shares of
Common Stock of the Company -
10.6(c) Technology License Agreement dated July 31, 1996 between Perceptive Scientific Imaging Systems, (9)
Inc. and PSII Acquisition Corp., a wholly-owned subsidiary of the Company (now known as
Perceptive Scientific Instruments, Inc.)
10.7 $7,000,000 Subordinated Note dated July 29, 1996 issued by the Company in favor of Digital (9)
Imaging Technologies, Inc.
10.8(a) Loan and Security Agreement dated as of May 5, 1998 among the Company, Perceptive Scientific (17)
Instruments, Inc., and StatSpin, Inc., on the one hand, and Foothill Capital Corporation, on
the other hand.
10.8(b) Intellectual Property Security Agreement dated as of May 5, 1998 between the Company and (17)
Foothill Capital Corporation
10.8(c) Copyright Security Agreement dated as of May 5, 1998 between the Company and Foothill Capital (17)
Corporation
10.8(d) Intellectual Property Security Agreement dated as of May 5, 1998 between Perceptive Scientific (17)
Instruments, Inc. and Foothill Capital Corporation
10.8(e) Copyright Security Agreement dated as of May 5, 1998 between Perceptive Scientific Instruments, (17)
Inc. and Foothill Capital Corporation
10.8(f) Security Agreement -- Stock Pledge dated as of May 5, 1998 between Perceptive Scientific (17)
Instruments, Inc. and Foothill Capital Corporation
10.8(g) Intellectual Property Security Agreement dated as of May 5, 1998 between StatSpin, Inc. and (17)
Foothill Capital Corporation
10.8(h) Amendment Number One to Loan and Security Agreement dated as of March 23, 1999 among the
Company, Perceptive Scientific Instruments, LLC, and StatSpin, Inc., on the one hand, and
Foothill Capital Corporation, (18)
21
24
on the other hand
10.8(i) Amendment Number One to Security Agreement -- Stock Pledge dated as of March 23, 1999 among the (18)
Company and Perceptive Scientific Instruments, LLC, on the one hand, and Foothill Capital
Corporation, on the other hand
10.8(j) Amendment to Copyright Security Agreement dated as of March 23, 1999 among the Company and (18)
Perceptive Scientific Instruments, LLC, on the one hand, and Foothill Capital Corporation, on
the other hand
10.8(k) Amendment to Intellectual Property Security Agreement dated as of March 23, 1999 among the (18)
Company and Perceptive Scientific Instruments, LLC, on the one hand, and Foothill Capital
Corporation, on the other hand
10.8(l) Amendment Number Two to Loan and Security Agreement dated as of March 19, 1999 among the (18)
Company, Perceptive Scientific Instruments, LLC, and StatSpin, Inc., on the one hand, and
Foothill Capital Corporation, on the other hand.
10.8(m) Amendment Number Three to the Loan and Security Agreement dated as of April 16, 1999 among
the Company, Perceptive Scientific Instruments, LLC, and StatSpin, Inc., on the one hand,
and Foothill Capital Corporation, on the other hand --
10.8(o) Warrant to Purchase Common Stock dated June 1, 1997 issued to City National Bank (13)
10.8(p) Warrant to Purchase Common Stock dated July 1, 1997 issued to City National Bank (13)
10.9(a) Common Stock Purchase Warrant dated December 31, 1996 issued to Thermo Amex Convertible Growth (2)
Fund I, L.P.
10.9(b) Registration Rights Agreement dated December 31, 1996 by and between the Company and Thermo (2)
AMEX Convertible Growth Fund I, L.P.
24 Consent of PricewaterhouseCoopers LLP --
27 Financial Data Schedule 1999 --
99 Disclosure Regarding Risk Factors And Forward-Looking Statements --
Exhibits followed by a number in parenthesis are incorporated by
reference to the similarly numbered Company document cited below:
(1) Current Report on Form 8-K dated August 13, 1987 and Quarterly Report on
Form 10-Q for the quarter ended September 30, 1993.
(2) Current Report on Form 8-K dated January 15, 1997.
(3) Quarterly Report on Form 10-Q for the quarter ended June 30, 1999.
(4) Current Report on Form 8-K dated January 26, 2000.
(5) Quarterly Report on Form 10-Q for the quarter ended September 30, 1994.
(6) Registration Statement on Form S-3, as filed with the Securities and
Exchange Commission on March 27, 1996 (File No. 333-002001).
(7) Annual Report on Form 10-K for the year ended December 31, 1989,
Quarterly Report on Form 10-Q for the quarter ended September 30, 1993
and Annual Report on Form 10-K for the year ended December 31, 1994.
(8) Registration Statement on Form S-8, as filed with the Securities and
Exchange Commission on August 8, 1994 (File No. 33-82560).
(9) Quarterly Report on Form 10-Q for the quarter ended June 30, 1996.
(10) Registration Statement on Form S-8, as filed with the Securities and
Exchange Commission on July 16, 1997 (File No. 333-31393).
(11) Registration Statement on Form S-8, as filed with the Securities and
Exchange Commission on October 9, 1998 (File No. 333-65547).
(12) Current Report on Form 8-K dated July 15, 1988 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 1995.
(13) Annual Report on Form 10-K for the year ended December 31, 1997.
(14) Annual Report on Form 10-K for the year ended December 31, 1994.
(15) Quarterly Report on Form 10-Q for the quarter ended September 30, 1996.
(16) Quarterly Report on Form 10-Q for the quarter ended September 31, 1995.
(17) Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.
(18) Annual Report on Form 10-K for the year ended December 31, 1998.
22
25
(b) Reports on Form 8-K.
We did not file any reports on Form 8-K during the quarter ended
December 31, 1999.
(c) See (a)(3) above.
(d) See (a)(1) and (2) above.
23
26
SIGNATURES
Pursuant to the requirements of Section 13 of the Securities Exchange
Act of 1934, the Registrant has duly caused this report on Form 10-K to be
signed on its behalf by the undersigned, thereunto duly authorized, in
Chatsworth, California, on March 30, 2000.
INTERNATIONAL REMOTE IMAGING
SYSTEMS, INC.
By: /s/ John A O'Malley
John A. O'Malley
Chairman of the Board, President
and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Title Date
- --------- ----- ----
/s/ John A. O'Malley Chairman of the Board, President March 30, 2000
- --------------------------- and Chief Executive Officer
John A. O'Malley (Principal Executive Officer)
/s/ Donald E. Horacek Assistant Secretary and Controller March 30, 2000
- --------------------------- (Principal Accounting Officer)
Donald E. Horacek
/s/ Steven M. Besbeck Director March 30, 2000
- ---------------------------
Steven M. Besbeck
/s/ Thomas F. Kelley Director March 30, 2000
- ---------------------------
Thomas F. Kelley
/s/ Richard G. Nadeau Director March 30, 2000
- ---------------------------
Richard G. Nadeau
27
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders
of International Remote Imaging Systems, Inc.
In our opinion, the consolidated financial statements listed in the
index appearing under Item 14(a)1 present fairly, in all material respects, the
financial position of International Remote Imaging Systems, Inc., and its
subsidiaries at December 31, 1999 and 1998, and the results of their operations
and their cash flows for each of the three years in the period ended December
31, 1999, in conformity with accounting principles generally accepted in the
United States. In addition, in our opinion, the financial statement schedule
listed in the index appearing under Item 14(a)2 presents fairly, in all material
respects, the information set forth therein when read in conjunction with the
related consolidated financial statements. These financial statements and
financial statement schedule are the responsibility of the Company's management;
our responsibility is to express an opinion on these financial statements and
financial statement schedule based on our audits. We conducted our audits of
these statements in accordance with auditing standards generally accepted in the
United States which require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.
/s/ PricewaterhouseCoopers LLP
Los Angeles, California
March 17, 2000
F-1
28
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS
ASSETS
At December 31,
--------------------------------
1998 1999
------------ ------------
Current assets:
Cash and cash equivalents $ 389,495 $ 2,034,593
Accounts receivable, net of allowance for doubtful
accounts of $271,544 in 1998 and $516,047 in 1999 5,615,799 6,444,865
Inventories 4,503,446 3,360,468
Prepaid expenses and other current assets 251,483 355,935
Deferred tax asset 942,589 1,005,908
------------ ------------
Total current assets 11,702,812 13,201,769
Property and equipment, at cost, net of accumulated depreciation 2,004,661 1,553,942
Purchased intangibles 7,512,100 258,295
Software development costs, net of accumulated amortization of
$1,558,597 in 1998 and $1,782,410 in 1999 1,097,907 474,616
Deferred tax asset 7,914,129 10,351,336
Other assets 1,875,475 821,167
------------ ------------
Total assets $ 32,107,084 $ 26,661,125
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings $ 464,769 $ 655,036
Current portion of long-term debt 1,742,027 1,200,000
Accounts payable 2,871,613 2,466,389
Accrued expenses 2,259,802 2,647,975
Deferred income - service contracts and other 794,688 1,140,737
------------ ------------
Total current liabilities 8,132,899 8,110,137
Subordinated note payable 7,000,000 7,000,000
Deferred income - service contracts and other 274,798 829,281
Notes payable, long-term portion 1,700,000 500,000
------------ ------------
Total liabilities 17,107,697 16,439,418
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.01 par value; Authorized: 3,000,000 shares:
Convertible Series A Shares issued and outstanding: 1998 - 3,000, 1999 - none
($3,000,000 liquidation preference) 30 --
Callable Series B Shares issued and outstanding: 1998 - none, 1999 - 198,000
($594,000 liquidation preference) -- 1,980
Common stock, $.01 par value
Authorized: 15,600,000 shares
Shares issued and outstanding: 1998 - 6,432,875, 1999 - 9,347,325 64,328 93,473
Additional paid-in capital 38,134,290 39,529,777
Unearned compensation (204,294)
(153,108)
Foreign currency translation adjustment 47,510 67,207
Accumulated deficit (23,042,477) (29,317,622)
------------ ------------
Total shareholders' equity 14,999,387 10,221,707
------------ ------------
Total liabilities and shareholders' equity $ 32,107,084 $ 26,661,125
============ ============
- ---------------
The accompanying notes are an integral part of
these consolidated financial statements.
F-2
29
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Year Ended December 31,
----------------------------------------------------
1997 1998 1999
------------ ------------ ------------
Sales of IVD imaging systems ............................... $ 5,612,308 $ 4,985,718 $ 6,505,821
Sales of IVD imaging system supplies and service ........... 10,061,314 11,785,184 13,611,676
Sales of small instruments and supplies .................... 4,447,418 4,345,304 5,297,385
Royalty and license revenues ............................... 603,076 464,972 310,587
------------ ------------ ------------
Net revenues ............................................... 20,724,116 21,581,178 25,725,469
------------ ------------ ------------
Cost of goods - IVD imaging systems ........................ 3,361,929 3,265,761 4,310,069
Cost of goods - IVD imaging system
supplies and service ..................................... 4,891,654 5,436,253 5,982,376
Cost of goods - small instruments
and supplies ............................................. 2,345,909 2,378,206 2,765,261
------------ ------------ ------------
Cost of goods sold ......................................... 10,599,492 11,080,220 13,057,706
------------ ------------ ------------
Gross margin ............................................... 10,124,624 10,500,958 12,667,763
Marketing and selling ...................................... 3,155,736 3,228,827 3,300,576
General and administrative ................................. 2,597,488 2,719,517 3,463,345
Research and development, net .............................. 1,600,313 1,879,226 1,124,240
Amortization of intangibles ................................ 425,576 278,015 230,784
Unusual charges (Note 16) .................................. 1,338,338 193,186 4,158,894
------------ ------------ ------------
Total operating expenses ................................... 9,117,451 8,298,771 12,277,839
Operating income ........................................... 1,007,173 2,202,187 389,924
Other income (expense):
Interest income ......................................... 52,354 33,935 35,310
Interest expense ........................................ (1,208,131) (1,162,634) (966,001)
Other income (expense) .................................. 56,423 13,462 (16,255)
------------ ------------ ------------
Income (loss) from continuing operations before
benefit (provision) for income taxes ..................... (92,181) 1,086,950 (557,022)
Income tax benefit (provision).............................. 34,107 (420,136) (530,902)
------------ ------------ ------------
Income (loss) from continuing operations ................... (58,074) 666,814 (1,087,924)
Loss from operations of discontinued segment, net of tax benefit of
of $258,893, $539,876 and $2,958,566, respectively ......... (445,214) (1,051,587) (5,187,221)
------------ ------------ ------------
F-3
30
For the Year Ended December 31,
-------------------------------------------------------
1997 1998 1999
------------- ------------- -------------
Net loss ....................................... (503,288) (384,773) (6,275,145)
Less imputed preferred stock dividend .......... (450,000) -- --
------------- ------------- -------------
Net loss attributable to common shareholders ... $ (953,288) $ (384,773) $ (6,275,145)
============= ============= =============
Income (loss) per share - basic:
Income (loss) from continuing operations ..... $ (0.01) $ 0.11 $ (0.15)
Loss from operations of discontinued segment (0.07) (0.17) (0.71)
Imputed preferred dividends ................ (0.08) -- --
------------- ------------- -------------
Loss per share attributable to common
shareholders - basic ......................... $ (0.16) $ (0.06) $ (0.86)
============= ============= =============
Income (loss) per share- diluted:
Income (loss) from continuing operations ..... $ (0.01) $ 0.09 $ (0.15)
Loss from operations of discontinued segment.. (0.07) (0.14) (0.71)
Imputed preferred dividends .................. (0.08) -- --
------------- ------------- -------------
Loss per share attributable to common
shareholders --diluted ....................... $ (0.16) $ (0.05) $ (0.86)
============= ============= =============
Weighted average number of
common shares outstanding - basic ........... 6,019,041 6,310,312 7,260,390
============= ============= =============
Weighted average number of
common shares outstanding - diluted .......... 6,019,041 7,688,202 7,260,390
============= ============= =============
- ---------------
The accompanying notes are an integral part of these
consolidated financial statements.
F-4
31
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Convertible Series A Additional
Preferred Stock Common Stock Paid-In Treasury
Shares Amount Shares Amount Capital Stock
------ ------ ------ ------ ------- -----
Balance December 31, 1996 ............. 3,000 $30 5,911,890 $59,118 $36,311,535 $(103,500)
Common stock issued
On exercise of stock options .......... -- -- 13,901 139 33,466 --
Common stock issued under Employee
Stock Purchase Plan:
For Cash .............................. -- -- 34,964 350 140,458 --
for Services .......................... -- -- 34,964 350 140,458 --
Issuance of stock options for
services ........................... -- -- -- -- 73,680 --
Common stock and warrants to purchase
common stock issued for cash on
exercise of warrants .................. -- -- 188,633 1,886 676,492 --
Issuance of common stock and warrants
in satisfaction of accounts payable ... -- -- 75,376 754 282,947 --
Issuance of warrants to purchase
common stock in connection with bank
debt renewal .......................... -- -- -- -- 129,500 --
Amortization of unearned
compensation .......................... -- -- -- -- -- --
Foreign currency translation .......... -- -- -- -- -- --
adjustment
Net loss .............................. -- -- -- -- -- --
----- --- --------- ------- ----------- ---------
Balance,
December 31, 1997 .................. 3,000 $30 6,259,728 $62,597 $37,788,536 $(103,500)
Foreign Currency
Unearned Translation Accumulated
Compensation Adjustment Deficit Total
------------ ---------------- ------- -----
Balance December 31, 1996 ............... $(385,879) $ 37,791 $(22,154,416) $ 13,764,679
Common stock issued
On exercise of stock options ............ -- -- -- 33,605
Common stock issued under Employee
Stock Purchase Plan:
For Cash ................................ -- -- -- 140,808
for Services ............................ (140,808) -- -- --
Issuance of stock options for services... (73,680) -- -- --
Common stock and warrants to purchase
common stock issued for cash on
exercise of warrants .................... -- -- -- 678,378
Issuance of common stock and warrants
in satisfaction of accounts payable ..... -- -- -- 283,701
Issuance of warrants to purchase
common stock in connection with bank
debt renewal ............................ -- -- -- 129,500
Amortization of unearned
compensation ............................ 266,872 -- -- 266,872
Foreign currency translation ............ -- (1,914) -- (1,914)
adjustment
Net loss ................................ -- -- (503,288) (503,288)
--------- -------- ------------ ------------
Balance,
December 31, 1997 ..................... $(333,495) $ 35,877 $(22,657,704) $ 14,792,341
- -------------
The accompanying notes are an integral part of these
consolidated financial statements
F-5
32
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Convertible Series A Additional
Preferred Stock Common Stock Paid-In Treasury
Shares Amount Shares Amount Capital Stock
------ ------ ------ ------ ------- -----
Balance forward ......................... 3,000 $30 6,259,728 $ 62,597 $ 37,788,536 $(103,500)
Common stock issued
on exercise of stock options ............ -- -- 37,732 377 113,952 (25,932)
Common stock issued under Employee
Stock Purchase Plan:
for Cash ................................ -- -- 48,400 484 76,345 --
for Services ............................ -- -- 108,775 1,088 174,187
Issuance of stock options for services... -- -- -- -- 12,000 --
Common stock and warrants to purchase
common stock issued for cash on
exercise of warrants and issuance of
warrants, net of expenses ............... -- -- 12,778 128 39,905 --
Retire treasury stock ................... -- -- (34,538) (346) (129,086) 129,432
Charge for repricing options held by
non-employees ........................... -- -- -- -- 58,451 --
Amortization of unearned
compensation ............................ -- -- -- -- -- --
Foreign currency translation ............ -- -- -- -- -- --
adjustment
Net loss ................................ -- -- -- -- -- --
----- --- ---------- -------- ------------ ---------
Balance,
December 31, 1998 ..................... 3,000 $30 6,432,875 $ 64,328 $ 38,134,290 --
Foreign
Currency
Unearned Translation Accumulated
Compensation Adjustment Deficit Total
------------ ---------- ------- -----
Balance forward .......................... $(333,495) $35,877 $(22,657,704) $ 14,792,341
Common stock issued
on exercise of stock options ............. -- -- -- 88,397
Common stock issued under Employee
Stock Purchase Plan:
for Cash ................................. -- -- -- 76,829
for Services ............................. (126,049) -- -- 49,226
Issuance of stock options for services ... (12,000) -- -- --
Common stock and warrants to purchase
common stock issued for cash on
exercise of warrants and issuance of
warrants, net of expenses ................ -- -- -- 40,033
Retire treasury stock .................... -- -- -- --
Charge for repricing options held by
non-employees ............................ -- -- -- 58,451
Amortization of unearned
compensation ............................. 267,250 -- -- 267,250
Foreign currency translation ............. -- 11,633 -- 11,633
adjustment
Net loss ................................. -- -- (384,773) (384,773)
--------- ------- ------------ ------------
Balance,
December 31, 1998 ...................... $(204,294) $47,510 $(23,042,477) $ 14,999,387
- ---------------
The accompanying notes are an integral part of these
consolidated financial statements
F-6
33
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Convertible Series A Callable Series B
Preferred Stock Preferred Stock Common Stock
Shares Amount Shares Amount Shares Amount
------- ------- ------- ------ --------- -------
Balance forward.......................... 3,000 $30 -- -- 6,432,875 $64,328
Common stock issued under Employee
Stock Purchase Plan:
for Cash................................. 300,050 3,001
for Services............................ 20,400 204
Issuance of stock options for services... -- -- --
Issuance of Series B Convertible
Preferred Stock and common stock in
connection with litigation settlement.... 198,000 $1,980 594,000 5,940
Conversion of Series A Preferred Stock... (3,000) (30) 2,000,000 20,000
Amortization of unearned
compensation.............................
Foreign currency translation
adjustment...............................
Net loss.................................
Balance,
December 31, 1999...................... -- -- 198,000 $1,980 9,347,325 $93,473
======= ======= ======= ====== ========= =======
Foreign
Additional Currency
Paid-In Unearned Translation Accumulated
Capital Compensation Adjustment Deficit Total
----------- --------- ----------- ------------ -----------
Balance forward.......................... $38,134,290 $(204,294) $47,510 $(23,042,477) $14,999,387
Common stock issued under Employee
Stock Purchase Plan:
for Cash................................. 220,161 (111,582) 111,580
for Services............................. 15,096 (7,650) 7,650
Issuance of stock options for services... 12,000 (12,000) --
Issuance of Series B Convertible
Preferred Stock and common stock in
connection with litigation settlement.... 1,168,200 1,176,120
Conversion of Series A Preferred Stock... (19,970) --
Amortization of unearned
compensation............................. 182,418 182,418
Foreign currency translation 19,697 19,697
adjustment...............................
Net loss................................. (6,275,145) (6,275,145)
------------- -----------
Balance,
December 31, 1999...................... $39,529,777 $(153,108) $67,207 $(29,317,622) $10,221,707
=========== ========== ======= ============= ===========
- ---------------
The accompanying notes are an integral part of
these consolidated financial statements
F-7
34
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Year Ended December 31,
-------------------------------------------------
1997 1998 1999
----------- ----------- -----------
Cash flows from operating activities:
Net loss .................................................. $ (503,288) $ (384,773) $(6,275,145)
Adjustments to reconcile net loss to net cash
provided by operations:
Deferred tax benefit ...................................... (403,000) (212,418) (2,500,526)
Depreciation and amortization ............................. 3,413,125 2,475,169 2,006,332
Provision for impairment of certain assets ................ -- -- 8,160,978
Common stock and stock option compensation ................ 266,872 325,701 182,417
Litigation settlement payable in equity securities ....... -- -- 1,520,371
(Gain) loss on disposal of property and equipment ......... 62,844 -- (87,158)
Allowance for doubtful accounts ........................... 177,974 119,296 534,653
Changes in assets and liabilities:
Accounts receivable - trade and other ..................... (153,983) (466,176) (931,541)
Service contracts, net .................................... 201,505 29,300 405,695
Inventories ............................................... 911,563 (880,254) 850,661
Prepaid expenses and other current assets ................. (66,386) (15,010) (105,939)
Other assets .............................................. (59,339) (235,926) (14,382)
Accounts payable .......................................... (1,686,728) 260,790 (399,525)
Accrued expenses .......................................... 84,071 (27,557) 419,087
Deferred income - other ................................... (279,591) (28,550) --
----------- ----------- -----------
Net cash provided by operating activities ................... 1,965,639 959,592 3,765,978
----------- ----------- -----------
Cash flows from investing activities:
Acquisition of property and equipment ..................... (949,841) (1,026,475) (438,069)
Sales of property and equipment ........................... -- -- 125,000
Acquisition of business and product line, net of
cash acquired or adjustments to cost of business ..... -- 167,790
Software development costs ................................ (534,855) (352,797) (367,502)
Maturities of securities .................................. 642,589 25,000 --
Acquisition of other assets ............................... (30,000) -- --
----------- ----------- -----------
Net cash used by investing activities ....................... (872,107) (1,186,482) (680,571)
----------- ----------- -----------
Cash flows from financing activities:
Issuance of common and preferred stock and warrants
for cash ................................................. 907,791 205,259 111,580
Installment payment on repurchase of common stock ......... (545,057) -- --
Borrowings on credit facility ............................. 3,895,000 8,558,550 8,903,395
Repayments on credit facility ............................. (4,879,755) (7,843,781) (8,713,128)
Repayments of notes payable and capital lease ............. (2,600,000) (1,611,509) (1,753,390)
Deferred stock or debt issuance costs ..................... -- (188,937) --
----------- ----------- -----------
Net cash used in financing activities ....................... (3,222,021) (880,418) (1,451,543)
----------- ----------- -----------
Effect of foreign currency rate fluctuation on
cash and cash equivalents ................................ (3,185) 25,942 11,234
----------- ----------- -----------
Net increase (decrease) in cash and cash equivalents ...... (2,131,674) (1,081,366) 1,645,098
Cash and cash equivalents at beginning of year ............ 3,602,535 1,470,861 389,495
----------- ----------- -----------
Cash and cash equivalents at end of year .................. $ 1,470,861 $ 389,495 $ 2,034,593
=========== =========== ===========
Supplemental schedule of non-cash financing activities:
Non cash issuance of common stock and common stock
warrants ............................................... $ 562,689 $ 234,755 $ 138,881
Issuance of warrants in connection
with development agreements and for other assets ....... 65,000 -- --
Unpaid common stock issuance costs ........................ 55,000 -- --
Issuance of notes payable for accrued liabilities ......... 1,042,027 -- --
Equipment acquired through issuance of capital lease ...... -- 70,000 --
Supplemental disclosure of cash flow information:
Cash paid for income taxes ................................ -- 213,407 57,468
Cash paid for interest .................................... 1,104,605 1,093,253 838,122
- ---------------
The accompanying notes are an integral part of
these consolidated financial statements.
F-8
35
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Year ended December 31,
---------------------------------------------
1997 1998 1999
--------- --------- -----------
Net loss .............................. $(503,288) $(384,773) $(6,275,145)
Other comprehensive income (loss),
foreign currency translation
adjustment ....................... (1,914) 11,633 19,697
--------- --------- -----------
Comprehensive loss .................... $(505,202) $(373,140) $(6,255,448)
========= ========= ===========
- -------------------
The accompanying notes are an integral part of these
consolidated financial statements.
F-9
36
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. FORMATION AND BUSINESS OF THE COMPANY.
International Remote Imaging Systems, Inc. and its subsidiaries
(collectively "IRIS" or the "Company"), was incorporated in California in 1979
and reincorporated during 1987 in Delaware. The Company designs, develops,
manufactures and markets in vitro diagnostic ("IVD") equipment, including IVD
imaging systems based on patented and proprietary automated intelligent
microscopy ("AIM") technology, as well as special purpose centrifuges and other
small instruments for automating microscopic procedures performed in clinical
laboratories.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting periods. The significant estimates in the preparation of the
consolidated financial statements relate to the assessment of the carrying value
of accounts receivables, inventories, purchased intangibles, estimated
provisions for warranty costs and deferred tax assets. Actual results could
differ from those estimates.
Principles of Consolidation
The financial statements include the accounts of International Remote
Imaging Systems, Inc. and its subsidiaries. All intercompany accounts and
transactions have been eliminated in the consolidated financial statements.
Foreign Currency
The financial statements of the Company's foreign subsidiary are
translated into U.S. dollars using the exchange rate prevailing at each balance
sheet date for assets and liabilities and average exchange rates for each
reporting period for revenues and expenses. Translation adjustments are recorded
directly to a separate component of shareholders' equity. Gains and losses
resulting from foreign currency transactions are included in operations.
Cash Equivalents and Short-Term Investments
Short-term investments principally include certificates of deposit and
debt instruments of the United States Government with maturities greater than
three months and less than one year. For purposes of the statement of cash
flows, IRIS considers all highly liquid debt instruments purchased with a
remaining maturity of three months or less when purchased to be cash
equivalents. IRIS places its cash and investments with high credit quality
financial institutions. At times, these deposits may be in excess of the
federally insured limit.
Accounts Receivable
IRIS sells predominantly to entities in the healthcare industry. IRIS
grants uncollateralized credit to its customers, primarily hospitals, clinical
and research laboratories, and distributors. IRIS performs ongoing credit
evaluations of its customers before granting uncollateralized credit. The
Company does not have any single customer which accounts for 10% or more of its
consolidated revenues.
F-10
37
Inventories
Inventories are carried at the lower of cost or market on a first in,
first out basis. Provision for potentially obsolete or slow-moving inventory is
made based on management's analysis of inventory levels and future sales
forecasts.
Property and Equipment and Depreciation
Property and equipment are recorded at cost, less accumulated
depreciation and amortization. Depreciation is generally computed using the
straight-line method over three to five years, the estimated useful lives of the
assets. Leasehold improvements are amortized over the lesser of their useful
life or the remaining term of the lease.
Costs of maintenance and repairs are charged to expense when incurred;
costs of renewals and betterments are capitalized. Upon sale or retirement, the
cost and related accumulated depreciation are eliminated from the respective
accounts, and the resulting gain or loss is included in current income.
Purchased Intangibles
Purchased intangibles are recorded at cost and consist of goodwill,
acquired technology and know-how and international distribution channel, and are
being amortized on a straight-line basis over ten years, six years and
twenty-five years, respectively. The realizability of purchased intangibles is
evaluated periodically as events or circumstances indicate a possible inability
to recover the carrying amount. Such evaluation is based on various analysis,
including cash flow and profitability projections. The analysis necessarily
involves significant management judgement to evaluate the capacity of an
acquired business to perform within projections. In the event the projected
undiscounted cash flows are less than net book value of the assets, the carrying
value of the assets will be written down to their fair value.
Software Development Costs
The Company capitalizes certain software development costs for new
products and product enhancements once all planning, designing, coding and
testing activities necessary to establish that the product can be produced to
meet its design specifications are completed, and concludes capitalization when
the product is ready for general release. Research and development costs
relating to software development are expensed as incurred. Amortization of
capitalized software development costs is provided on a product-by-product basis
at the greater of the amount computed using (a) the ratio of current revenues
for a product to the total of current and anticipated future revenues or (b) the
straight-line method over the remaining estimated economic life of the product.
Generally, an original estimated economic life of one and one half years to
three years is assigned to capitalized software development costs. Amortization
expense of software development costs, excluding the write off of costs relating
to the White IRIS of $796,887 (Note 16) in 1999, was $375,721, $334,996 and
$223,813 for 1997, 1998 and 1999, respectively.
Deferred Warrant Costs
Deferred warrant costs are included in other assets and result from the
issuance of warrants in conjunction with various development, distribution and
technology license agreements. These costs were generally being amortized over
the estimated term of the related agreements. During 1999, as a result of
certain events described in Note 16, a charge of $807,244 was recorded for the
write-down of this asset in the third quarter of 1999.
Long-Lived Assets
The Company identifies and records impairment losses for long-lived
assets whenever events or changes in circumstances result in the carrying amount
of the assets exceeding the sum of the expected future undiscounted cash flows
associated with such assets. The measurement of the impairment losses recognized
is based on the difference between the fair values and the carrying amounts of
the assets. During 1997, as a result of a distributor notifying the Company
that they would no longer carry the digital refractometer line,
F-11
38
a $704,579 charge was recorded for the write-down of long-lived assets in the
fourth quarter of 1997. As described in Notes 7 and 16, a $8,160,978 charge was
recorded for the write-down of long-lived assets in the third quarter of 1999.
Stock Based Compensation
The Company has adopted the disclosure-only provisions of SFAS No. 123,
"Accounting for Stock-Based Compensation." SFAS No. 123 defines a fair value
based method of accounting for an employee stock option. Fair value of the stock
option is determined considering factors such as the exercise price, the
expected life of the option, the current price of the underlying stock and its
volatility, expected dividends on the stock, and the risk-free interest rate for
the expected term of the option. Under the fair value based method, compensation
cost is measured at the grant date based on the fair value of the award and is
recognized over the service period. Pro forma disclosures for entities that
elect to continue to measure compensation cost under the intrinsic method
provided by Accounting Principles Board Opinion No. 25 must include the effects
of all awards granted in fiscal years that begin after December 15, 1994. An
expense is recognized for common stock, warrants or options issued or repriced,
for services rendered by non-employees based on the estimated fair value of the
security exchanged.
Revenue Recognition
IRIS derives revenue from the sale of IVD imaging systems, sales of
supplies and service for its IVD imaging systems and sales of small laboratory
instruments and related supplies. IRIS generally recognizes product revenues
once all of the following conditions have been met: a) an authorized purchase
order has been received in writing, b) customer credit worthiness has been
established, and c) delivery of the product to the customer designated location
has occurred. Estimated installation expense is recognized at the time of
delivery.
IRIS recognizes service revenues ratably over the term of the service
period, which typically ranges from twelve to sixty months. Payments for service
contracts are generally made in advance. Deferred revenue represents the
revenues to be recognized over the remaining term of the service contracts.
Warranties
IRIS recognizes the full estimated cost of warranty expense at the time
of product delivery.
Research and Development Expenditures
Except for certain software development costs required to be capitalized
as described above (see Software Development Costs), research and development
expenditures are charged to operations as incurred. Net research and development
expense includes total research and development costs incurred, including costs
incurred under research and development grants and contracts, less costs
reimbursed under research and development contracts.
Income Taxes
IRIS accounts for income taxes in accordance with SFAS No. 109
"Accounting for Income Taxes," which requires recognition of deferred tax
liabilities and assets for the expected future tax consequences of events that
have been included in the financial statements or tax returns. Under this
method, deferred tax liabilities and assets are determined based on the
differences between the financial statement and the tax bases of assets and
liabilities using enacted tax rates in effect for the year in which the
differences are expected to reverse. Valuation allowances are established when
necessary to reduce deferred tax assets to the amount expected to be realized.
Income tax expense represents the tax payable for the period and the change
during the period in deferred tax assets and liabilities.
Marketing Costs
F-12
39
All costs related to marketing and advertising the Company's products
are expensed at the time the advertising takes place.
Fair Value of Financial Instruments
The amount recorded for financial instruments in the Company's
consolidated financial statements approximates fair value as defined in SFAS No.
107, "Disclosures about Fair Value of Financial Instruments," except for the
subordinated note described in Note 9 of which the fair value is not readily
determinable.
Earnings Per Share
Basic earnings per share is computed by dividing net income (loss) by
the weighted average number of common shares outstanding. Diluted earnings per
share is computed by dividing net income (loss) by the weighted average number
of common shares and common stock equivalents outstanding, calculated on the
treasury stock method. Common stock equivalents are excluded from the
computation when their effect is antidilutive.
Segment Reporting
In the second quarter of 1998, the Company adopted SFAS No. 131,
"Disclosures about Segments of an Enterprise and Related Information". SFAS No.
131 supersedes SFAS No. 14, "Financial Reporting for Segments of a Business
Enterprise," replacing the "industry segment" approach with the "management"
approach. The management approach designates the internal organization that is
used by management for making operating decisions and assessing performance as
the source of the Company's reportable segments, SFAS No. 131 also requires
disclosures about products and services, geographic areas, and major customers.
The adoption of SFAS No. 131 did not affect results of operations or financial
position but did affect the disclosure of segment information. See Note 17 --
"Segment and Geographic Information".
Reclassifications
Certain reclassifications have been made to the 1997 and 1998 financial
statements to conform with the 1999 presentation.
Certain Risks and Uncertainties
Dependence on Instrument Sales: The Company derives most of its revenues
from the sale of The Yellow IRIS urinalysis workstations, and related supplies
and services. These instruments have list prices ranging from approximately
$100,000 to $195,000 depending on model and configuration, and relatively modest
declines in unit sales or gross margins for either product line could have a
material adverse effect on the Company's revenues and profits.
Reliance on Single Source Suppliers: Certain key components of the
Company's instruments are manufactured according to the Company's specifications
or are available only from single suppliers. For example, Roche Diagnostics is
the sole supplier for the Company's proprietary CHEMSTRIP/IRIStrip urine test
strips and related test reader used in The Yellow IRIS Models 300 and 500. From
time to time, single source suppliers have discontinued production of key
components or encountered production problems which potentially could have a
material adverse effect on instrument sales. Although, in the past, the Company
has successfully transitioned to new components to replace discontinued
components, there can be no assurance that the Company can always successfully
transition to satisfactory replacement components or that the Company will
always have access to adequate supplies of discontinued components on
satisfactory terms during the transition period. The Company's inability to
transition successfully to replacement components or to secure adequate supplies
of discontinued components on satisfactory terms could have a material adverse
effect on the Company.
F-13
40
New Accounting Pronouncements
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements," which provides the SEC's views on applying generally accepted
accounting principles to selected revenue recognition issues. The Company is
presently evaluating the impact, if any, that this bulletin may have on the
Company's revenue recognition policy.
3. COMPREHENSIVE INCOME.
The Company's components of comprehensive income (loss) are net income
(loss) and foreign currency translation adjustments. No tax effect has been
allocated to the foreign currency translation adjustment for the periods
presented.
The following is a reconciliation of accumulated other comprehensive
income balance for the three years ended December 31, 1999:
For the Years Ended December 31,
-------------------------------------
1997 1998 1999
-------- ------- -------
Beginning balance $ 37,791 $35,877 $47,510
Current period change (1,914) 11,633 19,697
-------- ------- -------
Ending balance $ 35,877 $47,510 $67,207
======== ======= =======
4. INVENTORIES.
Inventories consist of the following:
At December 31,
---------------------------
1998 1999
---------- ----------
Finished goods ............................ $1,647,028 $ 842,952
Work-in-process ........................... 432,569 350,424
Raw materials, parts and sub-assemblies ... 2,423,849 2,167,092
---------- ----------
$4,503,446 $3,360,468
========== ==========
5. PROPERTY AND EQUIPMENT.
Property and equipment consist of the following:
At December 31,
------------------------------
1998 1999
----------- -----------
Leasehold improvements .......... $ 414,303 $ 448,231
Furniture and fixtures .......... 281,280 377,797
Machinery and equipment ......... 4,593,847 4,583,126
Tooling, dies and molds ......... 796,355 995,560
Rental units .................... 1,059,045 1,019,898
----------- -----------
7,144,830 7,424,612
Less accumulated depreciation ... (5,140,169) (5,870,670)
----------- -----------
$ 2,004,661 $ 1,553,942
=========== ===========
Property and equipment includes $3,791,505 and $3,463,223 respectively,
at December 31, 1998 and 1999, of fully depreciated assets which remain in
service. Depreciation expense was $983,003, $926,655 and $854,022 for 1997, 1998
and 1999 respectively.
F-14
41
6. EQUIPMENT LEASING
The components of net investment in sales-type leases recorded in other
assets are as follows at December 31, 1998 and 1999.
1998 1999
--------- ---------
Total minimum lease payments $ 563,364 $ 467,820
Less: Estimated executory costs
Including profit thereon (180,268) (145,572)
--------- ---------
Net minimum lease payments 383,096 322,248
Less: Unearned income (120,189) (101,193)
--------- ---------
Net investment in sales-type leases 262,907 221,055
Less: Current portion (52,852) (56,424)
--------- ---------
$ 210,055 $ 164,631
========= =========
Any lease that does not meet the criteria for a sales-type or a
financing lease is accounted for as an operating lease. Under these leases the
Company also provides supplies and services. Generally operating leases are for
periods less than one year and contain provisions for renewal and early
termination penalties. The cost of leased systems is depreciated to a zero
value on a straight-line basis over five years. Accumulated depreciation on
leased systems was $413,992, and $606,087 at December 31, 1998 and 1999,
respectively.
Future minimum lease payments due from customers under sales-type leases
and noncancellable operating leases as of December 31, 1999 are as follows:
Sales-Type Leases Operating Leases
----------------- ----------------
2000 $119,124 $430,464
2001 119,124 24,367
2002 119,124 --
2003 86,868 --
2004 23,580 --
-------- --------
$467,820 $454,831
======== ========
7. PURCHASED INTANGIBLES.
Purchased intangibles, at cost, consist of the following:
At December 31,
----------------------------
1998 1999
----------- ---------
Goodwill ............................. $ 383,108 $ 383,108
International distribution channel ... 5,403,938 --
Acquired technology and know-how ..... 3,960,904 --
----------- ---------
9,747,950 383,108
Less accumulated amortization ........ (2,235,850) (124,813)
----------- ---------
Total ................................ $ 7,512,100 $ 258,295
=========== =========
The Company acquired most of these intangibles in connection with the
1996 acquisition of its genetic analysis business which is currently operated
through Perceptive Scientific Instruments, Inc, a wholly-owned subsidiary.
Following the recent transition to a new chief executive officer, the Company
reviewed the recoverability of these assets as part of an overall reassessment
of its business. Based primarily upon this segment's continued losses and
generally weakened market, the Company revised its forecasted cash flows
(undiscounted and without interest charges) from this business segment and
determined that they would be negative and insufficient to recover the cost of
these intangible assets. As a result, the Company wrote-off the remaining
unamortized amount of these intangible assets by recording a $6,556,847 charge
to earnings in the
F-15
42
third quarter of 1999 as an impairment loss. This charge has been included in
loss from discontinued operations (see Note 15).
8. ACCRUED EXPENSES.
Accrued expenses consist of the following:
At December 31,
---------------------------
1998 1999
---------- ----------
Accrued bonuses ............. $ 207,892 $ 382,223
Accrued commissions ......... 232,766 285,748
Accrued payroll ............. 7,015 43,186
Accrued vacation ............ 284,262 282,075
Accrued professional fees ... 206,955 243,838
Accrued warranty expense .... 441,771 394,874
Accrued interest ............ 138,817 122,824
Accrued - other ............. 740,324 893,207
---------- ----------
$2,259,802 $2,647,975
========== ==========
9. SHORT-TERM BORROWINGS AND NOTES PAYABLE.
At December 31, 1999, the outstanding amounts under the Company's credit
facility consists of $1.7 million of a $3.6 million term loan and $655,036 of a
$4.0 million revolving line of credit. Borrowings under the line of credit are
limited to a percentage of eligible accounts receivable. The Company had
approximately $2.0 million available under the line of credit at December 31,
1999. The term loan bears interest at the lender's prime rate (8.5% on December
31, 1999) plus 3.0% and is payable in monthly installments of $100,000. The
revolving credit line bears interest at the lender's prime rate plus 1.0%. The
credit facility is subject to minimum interest charges, prepayment penalties
and customary fees, is collateralized by a first priority lien on all assets of
the Company and matures in 2001. It also contains financial covenants based
primarily on tangible net worth and cash flows and imposes restrictions on
acquisition, capital expenditures and cash dividends.
The outstanding principal balance on the Subordinated Note was $7.0
million on December 31, 1999. The Subordinated Note bears interest at a fixed
rate of 8.5% per annum, payable in quarterly installments. The entire principal
is due on or before July 31, 2001. The Company may prepay the Subordinated Note
at any time without premium or penalty. Upon the issuance by the Company of
equity securities generating net proceeds in excess of $14.5 million, the
Company must apply fifty percent of the excess to the prepayment of the
Subordinated Note. The payment of principal and interest on the Subordinated
Note is subordinated in right of payment, to the extent and in the manner
provided therein, to the prior payment in full of the credit facility.
Annual maturities of long term borrowings are $1,200,000 (2000) and
$7,500,000 (2001).
10. INCOME TAXES.
The provision (benefit) for income taxes from continuing operations
consists of the following:
F-16
43
For the Year Ended December 31,
-------------------------------------------
1997 1998 1999
--------- --------- ---------
Current:
Federal $ -- $ -- $ 4,000
State 60,000 70,000 32,000
Foreign 50,000 23,000 36,000
--------- --------- ---------
110,000 93,000 72,000
--------- --------- ---------
Deferred:
Federal (132,000) 300,000 422,000
State (12,000) 27,000 37,000
--------- --------- ---------
(144,000) 327,000 459,000
--------- --------- ---------
$ (34,000) $ 420,000 $ 531,000
========= ========= =========
The provision (benefit) for income taxes from continuing operations
differs from the amount obtained by applying the federal statutory
income tax rate to income from continuing operations before benefit for income
taxes for the years ended December 31, 1997, 1998 and 1999 as follows:
For the Year Ended December 31,
-------------------------------------------
1997 1998 1999
--------- --------- ---------
Tax benefit computed at
Federal statutory rate ................ $ (31,000) $ 370,000 $(189,000)
Increase (decrease) in taxes due to:
Change in valuation allowance ......... -- -- 649,000
State taxes, net of federal benefit ... (2,000) 22,000 (11,000)
Nondeductible expenses ................ 20,000 38,000 38,000
Other ................................. (21,000) (10,000) $ 44,000
--------- --------- ---------
$ (34,000) $ 420,000 $ 531,000
========= ========= =========
At December 31, 1999, the Company had federal net operating loss
carryforwards of approximately $17.5 million and state net operating loss
carryforwards of approximately $2.3 million which expire in fiscal years
ending in 2000 through 2013. As of December 31, 1999, IRIS had investment tax,
research and experimentation and foreign tax credit carryforwards of $210,000
expiring in fiscal years through 2004.
The primary components of temporary differences which give rise to the
Company's net deferred tax asset at December 31, 1997, 1998 and 1999 are as
follows:
At December 31,
---------------------------------------------------
1997 1998 1999
----------- ------------ ------------
Depreciation and amortization .......... $ 961,000 $ 1,163,000 $ 4,519,000
Allowance for doubtful accounts ........ 99,000 100,000 115,000
Accrued liabilities .................... 598,000 332,000 683,000
Deferred revenue-service contracts ..... 138,000 232,000 193,000
Deferred research and development ...... 2,549,000 2,276,000 2,064,000
Net operating loss carryforwards ....... 6,112,000 6,337,000 5,969,000
Other .................................. 159,000 417,000 463,000
Valuation allowance .................... (2,000,000) (2,000,000) (2,649,000)
----------- ------------ ------------
$ 8,616,000 $ 8,857,000 $ 11,357,000
=========== ============ ============
At December 31, 1999, the Company increased the valuation allowance by
$649,000 based on its current assessment of operating results, net operating
loss carry-forwards scheduled to expire in the near term, and other factors.
Realization of deferred tax assets associated with net operating losses
("NOL") and tax credit carryforwards is dependent upon generating sufficient
taxable income prior to their expiration. Management believes that there is a
risk that certain of these NOL and tax credit carryforwards may expire unused
and accordingly, has established a
F-17
44
valuation allowance against them. Although realization is not assured for the
remaining deferred tax assets, management believes it is more likely than not
that they will be realized through future taxable income or alternative tax
strategies. However, the net deferred tax assets could be reduced in the near
term if management's estimates of taxable income during the carryforward period
are significantly reduced or alternative tax strategies are not available. The
Company will continue to review its valuation allowances and make adjustments,
if necessary. Also, although a valuation allowance has been provided against a
portion of its NOL's, should the Company undergo an ownership change as defined
in Section 382 of the Internal Revenue Code, the Company's NOL generated prior
to the ownership change would be subject to an annual limitation. If this
occurs, a further adjustment of the valuation allowance may be necessary.
11. CAPITAL STOCK.
Preferred Stock
On December 31, 1996, the Company sold (i) 3,000 shares of a new Series
A Convertible Preferred Stock ("Preferred Stock") with a liquidation value of
$1,000 per share. Each share of Preferred Stock was convertible into a number
of shares of common stock equal to the liquidation value of a share of Preferred
Stock divided by a conversion price. The Conversion Price was equal to the
lower of (i) 85% of the average closing bid price of the common stock for
the five consecutive trading days immediately preceding the conversion date (but
in no event less than $1.50) or (ii) $3.56. On October 1, 1999, the Series A
Preferred stockholder converted its investment into two million shares of common
stock. In 1997, for purposes of calculating earnings per share, the potential
discount on the conversion of the Preferred Stock was treated as an embedded
dividend to the preferred stockholders which reduces the amount of income
available to common stockholders.
During the year ended December 31, 1999, the Company successfully
completed a tender offer for the common stock of Poly UA Systems, Inc., a
Company-sponsored research and development entity. In exchange for the tendered
shares and a release of claims, the Company issued to the tendering stockholders
a total of 594,000 shares of common stock, 198,000 shares of a new Series B
Callable Preferred Stock and Series G Warrants to purchase an additional 594,000
shares of the Common Stock. The Series B shares have a liquidation preference of
$3 per share (or an aggregate liquidation preference of $594,000). The
"callable" feature entitles the Company to convert the preferred stock at any
time into a number of shares of common stock equal to the liquidation value
divided by the market price of the common stock at the time of conversion
(subject to a minimum value of $2 per share of common stock). The preferred
stock will automatically convert under the same formula on August 3, 2002, if
not converted sooner by the Company. The Series B Callable Preferred Stock is
non-voting, is not entitled to any preferred dividends and is not subject to any
mandatory or optional redemption provisions. The Company may not pay cash
dividends on the common stock or repurchase any shares of the common stock
without the written consent of the holders of a majority of the Series B
Callable Preferred Stock.
Shareholders' Rights Plan
The Company has a shareholders' rights plan under which each holder of a
share of common stock also has one right to purchase one one-thousandth of a
newly created Series C preferred share at $9 per one one-thousandth of a share.
The rights are not presently exercisable. Upon the occurrence of certain
"flip-in" events, each right becomes exercisable which then entitles its holder
to receive the number of common shares having an aggregate per share market
price equal to two times the purchase price. Upon certain "flip-over" events,
each right when exercised entitles its holder to receive common share of the
acquiring company having a value equal to two times the purchase price. One
flip-in event is when a person or group (an "acquiring person") acquires 20
percent or more of the company's common stock. Rights held by an acquiring
person are void. The Company may redeem the rights for one cent per share. The
rights expire on December 22, 2009.
Stock Issuances
F-18
45
During 1990, the IRIS Board of Directors adopted an Employee Stock
Purchase Plan designed to allow employees of the Company to buy its shares at
50% of the then current market price, provided that the employee agrees to hold
the shares purchased for a minimum of two years. The employee's 50% portion of
stock purchases under the plan may not exceed 15% of the employee's salary
during any year. The remaining 50% portion is recorded as deferred compensation
and amortized over the vesting period. The shares purchased pursuant to this
plan may not be transferred, except following the death of the employee or a
change in control, for a period of two years following the date of purchase.
During the period of the limitation on transfer, the Company has the option to
repurchase the shares at the employee's purchase price if the employee
terminates employment with the Company either voluntarily or as a result of
termination for cause. During 1997, 1998 and 1999 IRIS issued 69,928, 157,175
and 320,450 shares of common stock, respectively, in exchange for $281,616,
$252,104 and $238,462 in cash and services, respectively, under this plan
Stock Option Plans and Employee Benefit Plans
As of December 31, 1999, the Company had three stock option plans under
which it may grant non-qualified stock options, incentive stock options and
stock appreciation rights. No stock appreciation rights or incentive stock
options have been granted under these plans.
The following schedule sets forth options authorized, exercised,
outstanding and available for grant under the Company's three stock option plans
as of December 31, 1999.
Number of Option Shares
------------------------------------------------------
Available
Plan Authorized Exercised Outstanding for Grant
- ---- ---------- --------- ----------- ---------
1994 700,000 23,832 667,301 8,867
1997 600,000 -- 600,000 --
1998 600,000 -- 599,150 850
--------- --------- --------- -----
1,900,000 23,832 1,866,451 9,717
========= ========= ========= =====
The exercise price of options is determined by the Compensation
Committee. Payment of the exercise price may be made in cash or
with shares of common stock. The options generally vest over three years and
expire either five or ten years from the date of grant. On November 6, 1998, the
Board of Directors acted to reprice all outstanding stock options to a maximum
of $1.31 per share, the current market price as of that date. Also, any common
stock acquired upon exercise of the repriced options cannot be resold without
the Board of Directors approval until January 1, 2000.
IRIS has adopted the disclosure only provisions of Statement of
Financial Accounting Standards No. 123, "Accounting for Stock Based
Compensation." If compensation expense for the stock options had been determined
using "fair value" at the grant date for awards in 1997, 1998 and 1999,
consistent with the provisions of Statement of Financial Accounting Standards
No. 123, the Company's net loss and loss per share would have been reduced to
the pro forma amounts indicated below:
For the year ended December 31,
-------------------------------------------------------
1997 1998 1999
------------- ------------- -------------
Net loss attributable to
common stockholders as reported $ (953,288) $ (384,773) $ (6,275,145)
Net loss attributable to
common stockholders pro forma (1,604,718) (584,374) (6,665,244)
Loss per diluted share as reported $ (.16) $ (.06) $ (.86)
Loss per diluted share pro forma (.27) (.09) (.92)
The fair value of each option grant is estimated on the date of the
grant using the Black-Scholes option pricing model with the following weighted
average assumptions used for grants in 1997, 1998 and 1999.
For the year ended December 31,
-------------------------------
F-19
46
1997 1998 1999
---- ---- ----
Risk free interest rate 6.10% 4.98% 5.82%
Expected lives (years) 5 5 5
Expected volatility 54% 59% 74%
Expected dividend yield -- -- --
The pro forma calculations above are for informational purposes only.
Future calculations of the pro forma effects of stock options may vary
significantly due to changes in the assumptions described above as well as
future grants, and for forfeitures of stock options.
The following table sets forth certain information relative to stock
options during the years ended December 31, 1997, 1998 and 1999.
Option Price
------------------------------- Fair Value at
Weighted Grant Date
Shares Range Average Weighted Average
-----------------------------------------------------------------------------------
Outstanding at January 31, 1997 1,024,034 $1.90 to $6.22 $3.02 --
Granted 325,100 $3.19 to $4.50 $3.73 $3.84
Exercised (13,901) $1.90 to $3.03 $2.64 --
Canceled or expired (68,933) $2.59 to $6.22 $4.04 --
-----------------------------------------------------------------------------------
Outstanding at December 31, 1997 1,266,300 $3.03 to $4.50 $3.21 --
Granted 368,800 $0.81 to $4.25 $2.36 $2.36
Exercised (37,732) $3.03 $3.03
Canceled or expired (96,367) $3.03 to $4.00 $3.11 --
-----------------------------------------------------------------------------------
Outstanding at December 31, 1998 1,501,001 $0.81 to $4.50 $1.46
Granted 488,250 $0.69 to $1.38 $1.11 $1.11
Exercised -- -- -- --
Canceled or expired (122,800) $0.88 to $4.50 $2.35 --
--------- -------------- ----- -----
Outstanding at December 31, 1999 1,866,451 $0.69 to $4.38 $1.31 --
-----------------------------------------------------------------------------------
Outstanding at December 31, 1999
Weighted average life - 90 months 1,866,451 $1.31
Outstanding at December 31, 1998
Weighted average life - 82 months 1,501,001 $1.46
Outstanding at December 31, 1997
Weighted average life - 95 months 1,266,300 $3.21
Exercisable at December 31, 1999
Weighted average life - 58 months 1,200,066 $1.31
Exercisable at December 31, 1998
Weighted average life - 42 months 762,579 $1.46
Exercisable at December 31, 1997
Weighted average life - 32 months 537,167 $3.03
During the year ended December 31, 1999, the Company issued 150,000
options at $1-1/16, subject to the authorization of additional shares under an
existing stock option plan. If the Company is unable to obtain shareholder
approval of these options within twelve months, a stock appreciation right will
be issued for 125,000 of these options retroactive to the original issue date
with the same exercise price, duration and vesting as the original option. The
Company is accounting for these options as stock appreciation rights until
shareholder approval is obtained. No compensation expense relating to these
options was recognized in the current year due to the market value of the common
stock being below the exercise price at December 31, 1999.
F-20
47
In 1996, the Company adopted a 401(k) Plan. All employees are eligible
to participate in the plan. Contributions by the Company are discretionary.
Employees vest in amounts contributed by the Company immediately. The Company
contributed $46,844 and $45,352 to the plan for 1998 and 1999, respectively.
Warrants
At December 31, 1999, the following warrants to purchase common stock
were outstanding and exercisable:
Number of Shares Per Share Price Expiration Date
---------------- --------------- ---------------
50,000 $3.875 January 15, 2000
298,633 4.00 March 29, 2000
25,000 4.375 June 1, 2000
25,000 4.0625 July 1, 2000
123,000 7.80 September 28, 2000
875,000 3.56 July 31, 2001
84,270 3.56 December 31, 2001
10,000 4.31 May 15, 2002
297,000 2.00 August 6, 2002
297,000 1.00 August 6, 2002
12. COMMITMENTS AND CONTINGENCIES.
Leases
The Company leases real property under agreements which expire at
various times over the next three years. Certain leases contain renewal options
and generally require the Company to pay utilities, insurance, taxes and other
operating expenses.
Future minimum rental payments required under capital and operating
leases that have an initial term in excess of one year as of December 31, 1999,
are as follows:
Year Ended December 31 Capital Leases Operating Leases
- ---------------------- -------------- ----------------
2000 $ 17,011 $268,452
2001 16,894 195,357
2002 16,894 93,024
2003 16,894 --
2004 16,894 --
Years thereafter 2,816 --
-------- --------
$ 87,403 $556,833
======== ========
Rent expense under all operating leases during 1997, 1998 and 1999 was
$489,500, $514,555 and $530,000, respectively.
Other
IRIS has a licensing agreement with Cytocolor, Inc. relating to the use
of its patented leukocyte stain. Under the terms of the agreement, IRIS is
subject to the following future minimum royalty payments:
F-21
48
Year Ended December 31, Amount
- ----------------------- ------
2000 $ 20,000
2001 20,000
2002 20,000
2003 20,000
Years thereafter 200,000
--------
$280,000
========
Litigation
From time to time, the Company is party to certain litigation arising
from the normal course of business. Management believes that the resolution of
these matters will not have a material adverse effect on the Company's financial
position, results of operations or cash flows.
13. EARNINGS PER SHARE.
The computation of per share amounts for 1997, 1998 and 1999 is based on
the average number of common shares outstanding for the period. Options and
warrants to purchase 3,072,203 shares of common stock and 842,697 shares on
conversion of preferred stock were not considered in the computation of diluted
EPS for 1997 because their inclusion would have been antidilutive. Options and
warrants to purchase 3,951,354 shares of common stock and 297,000 shares on
conversion of preferred stock were not considered in the computation of diluted
EPS for 1999 because their inclusion would have been antidilutive.
The following is a reconciliation of shares used in computing basic and
diluted earnings per share for 1998:
1998
---------
Weighted average number of shares - basic 6,310,312
Effect of dilutive securities:
Options 325,258
Warrants --
Preferred stock 1,052,632
---------
Weighted average number of shares - diluted 7,688,202
=========
14. LICENSE.
Sysmex Corporation, formerly known as TOA Medical Electronics Co., Ltd.,
has developed several urine sediment analyzers under license from IRIS using
pre-1989 IRIS technology. IRIS received royalties under this license of
$513,000, $230,000 and $310,587 in 1997, 1998 and 1999, respectively.
15. DISCONTINUED OPERATIONS.
On March 17, 2000, the Company entered into a letter of intent for the
sale of its wholly-owned subsidiary, Perceptive Scientific Instruments, LLC
("PSI"), which comprised the Company's Genetic Analysis business segment.
Accordingly, in accordance with Accounting Principles Board Opinion No. 30,
"Reporting the Results of Operations," and Emerging Issues Task Force Issue No.
95-18, "Accounting and Reporting for a Discontinued Business Segment When the
Measurement Date Occurs After the Balance Sheet Date But Before the Issuance of
Financial Statements," the results of operations of PSI are presented in the
accompanying financial statements as discontinued operations.
The operating results of the discontinued segment are summarized as
follows:
For the year ended December 31,
--------------------------------------------------
F-22
49
1997 1998 1999
----------- ----------- ------------
Revenues $ 6,771,032 $ 5,936,301 $ 4,218,647
Costs and expenses excluding unusual charges 7,532,230 7,582,414 5,787,688
Unusual charges -- -- 6,556,847
Operating income (loss) (761,198) (1,646,113) (8,125,888)
Other Income (loss) 57,091 54,650 (19,900)
Loss from operations of discontinued segment
before income tax benefit (704,107) (1,591,463) (8,145,788)
Income tax benefit (258,893) (539,876) (2,958,567)
Loss from operations of discontinued segment (445,214) (1,051,587) (5,187,221)
The cash flow data of the discontinued segment included in the
consolidated statements of cash flows, is summarized as follows:
For the year ended December 31,
-------------------------------------------
1997 1998 1999
--------- --------- ---------
Cash flow (used in) from operations $(187,937) $(137,169) $ 279,321
Cash used by investing activities (402,880) (377,948) (230,166)
Effect of foreign currency fluctuations on cash equivalents 5,688 25,942 11,234
Cash provided (used) by discontinued operation (585,129) (489,174) 60,389
The net assets of the discontinued segment included in the consolidated
balance sheets, are summarized as follows:
As of December 31,
---------------------------
1998 1999
---------- ----------
Current assets $2,470,887 $1,585,151
Property and equipment 321,393 234,958
Deferred software costs 208,539 226,669
Intangible assets 7,622,028 --
Current Liabilities (1,431,206) (1,125,077)
Net assets 9,191,641 921,701
16. UNUSUAL CHARGES.
The results of operations for the year ended December 31, 1997 include
certain unusual charges to earnings of $1,338,338 primarily for the write-off of
deferred offering costs ($481,325), goodwill associated with the digital
refractometer line of business ($704,579) and certain legal expenses ($152,434)
related to patent litigation and arbitration against Digital Imaging
Technologies, Inc. ("DITI"), relating to the acquisition of PSI. Unusual charges
for the year ended December 31, 1998 totaled $193,186 and related primarily to
the arbitration matter.
The results of operations for year ended December 31, 1999 include
litigation settlement and other unusual charges totaling $4,158,894. These
charges primarily consist of (1) the settlement expense recorded in connection
with the tender offer for Poly U/A Systems, Inc. ($1,670,127), (2) the cost of
the arbitration with DITI ($391,831), (3) the write-off of deferred warrant
costs for technology rights from Poly U/A Systems ($807,244), (4) the write-off
of deferred costs related to The White IRIS leukocyte differential analyzer
program ($796,887), and (5) expenses in connection with the prior CEO's
retirement agreement ($443,805).
In September 1995, the Company and Poly U/A Systems Inc., a
Company-sponsored research and development entity ("Poly UA"), entered into a
joint development project for the development of several new products to enhance
automated urinalysis using the Company's technology. As part of the terms of the
project, the Company issued warrants to purchase 512,000 shares of its common
stock in exchange for rights to certain technology and began amortizing the cost
of these warrants. During the fall of 1998, the Company decided not to exercise
a previously negotiated $5.1 million option to acquire the remaining rights to
the technology through an acquisition of Poly UA. The Company later acquired 77%
of the Poly UA common stock from certain stockholders, primarily to avoid
litigation, in exchange for a package of Company securities. In connection with
this transaction, the Company recorded litigation settlement expense of
$1,520,371 in the first quarter of 1999 and $149,756 in subsequent quarters of
1999.
Following a recent transition to a new chief executive officer, the
Company conducted a reassessment of its
F-23
50
business and developed a new, near-term business plan. The technology rights
acquired in 1995 from Poly UA for warrants are not used in the new business
plan. As a result, the Company wrote-off the remaining unamortized cost of the
warrants ($807,244) in the third quarter of 1999 (included in unusual expenses).
Similarly, the Company elected not to include The White IRIS leukocyte
analyzer in its new, near-term business plan and therefore wrote off in the
third quarter $796,887 of capitalized software development costs (included in
unusual expenses) and $128,615 of inventory related to The White IRIS (included
in IVD systems cost of goods sold).
17. SEGMENT AND GEOGRAPHIC INFORMATION.
The Company's continuing operations are organized on the basis of
products and related services and under SFAS No. 131 operates in two segments:
(1) urinalysis and (2) small laboratory devices.
The urinalysis segment designs, develops, manufactures and markets IVD
systems based on patented and proprietary AIM technology for automating
microscopic procedures for urinalysis. In December 1997, this segment also began
distributing the UF-100 urine cell analyzer in the United States under an
existing agreement with its manufacturer. The segment also provides ongoing
sales of supplies and service necessary for the operation of installed
urinalysis workstations. In the United States, these products are sold through a
direct sales force. Internationally, these products are sold through
distributors.
The small laboratory devices segment designs, develops, manufactures and
markets a variety of benchtop centrifuges, small instruments and supplies. These
products are used primarily for manual specimen preparation and dedicated
applications in coagulation, cytology, hematology and urinalysis. These products
are sold worldwide through distributors.
The accounting policies of the segments are the same as those described
in the "Summary of Significant Accounting Policies" included in this annual
report for the year ended December 31, 1999. The Company evaluates the
performance of its segments and allocates resources to them based on earnings
before income taxes, excluding corporate charges ("Segment Profit").
F-24
51
The tables below present information about reported segments for the
three years ended December 31, 1999:
Small Unallocated
Laboratory Corporate
Urinalysis Devices Expenses Total
----------- ------------- ------------ ------------
For the Year Ended December 31, 1997:
Revenues $16,184,542 $ 4,539,574 -- $ 20,724,116
Interest income $ 34,673 $ 17,681 -- $ 52,354
Interest expense -- -- $ 1,208,131 $ 1,208,131
Depreciation and amortization $ 1,207,014 $ 936,005(1) $ 64,460 $ 2,207,479
Other noncash items $ 89,132 $ 88,842 -- $ 177,974
Unusual items $ 95,129 $ 704,579 $ 538,630 $ 1,338,338
Segment profit (loss) $ 2,720,558 $ 371,988 $ (3,184,727) $ (92,181)
Segment assets $10,872,075 $ 2,067,297 $ 8,615,750 $ 21,555,122
Investment in long-lived assets $ 1,080,419 $ 31,387 -- $ 1,111,806
For the Year Ended December 31, 1998:
Revenues $17,000,874 $ 4,580,304 -- $ 21,581,178
Interest income $ 20,123 $ 13,812 -- $ 33,935
Interest expense $ 5,147 -- $ 1,157,487 $ 1,162,634
Depreciation and amortization $ 1,069,208 $ 163,074 $ 114,818 $ 1,347,100
Other noncash items $ 71,058 $ 48,238 -- $ 119,296
Unusual items -- $ 193,186 $ 193,186
Segment profit (loss) $ 2,867,240 $ 1,079,027 $ (2,859,317) $ 1,086,950
Segment assets $10,880,771 $ 1,746,774 $ 8,856,692 $ 21,484,237
Investment in long-lived assets $ 950,260 $ 51,064 -- $ 1,001,324
For the Year Ended December 31, 1999:
Revenues $20,428,084 $ 5,297,385 -- $ 25,725,469
Interest income $ 32,546 $ 2,764 -- $ 35,310
Interest expense $ 5,155 -- $ 960,846 $ 966,001
Depreciation and amortization $ 2,552,196(2) $ 131,700 $ 47,572 $ 2,731,468
Other noncash items $ 472,011 $ (82,225) -- $ 389,786
Unusual items $ 1,732,746 -- $ 2,426,148 $ 4,158,894
Segment profit (loss) $ 3,676,900 $ 1,414,313 $ (5,648,235) $ (557,022)
Segment assets $11,068,096 $ 2,189,013 $ 11,357,238 $ 24,614,347
Investment in long-lived assets $ 517,854 $ 57,551 $ 575,405
(1) Includes writeoff totaling $704,579 relating to the goodwill associated with
the digital refractometer line of business.
(2) Includes writeoff totaling $1,604,131 relating to deferred warrant cost for
technology costs and deferred software costs.
Long-lived assets for continuing operations were all located in the
United States and totaled $4,338,183 and $2,646,393 as of December 31, 1998 and
1999, respectively.
The following is a reconciliation of segment assets to the consolidated
balance sheet as of December 31, 1998 and 1999:
1998 1999
------------ -----------
Segment assets from continuing operations ..... $ 21,484,237 $ 24,614,347
Assets of discontinued segment ................ 10,622,847 2,046,778
------------ ------------
$ 32,107,084 $ 26,661,125
============ ============
F-25
52
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
Additions
------------------------
Charged to Charged
Beginning cost and to other Ending
Balance expenses accounts Deductions Balance
---------- -------- ------- --------- ----------
Year Ended December 31, 1999
Allowance for Doubtful Accounts $ 271,544 $254,503 -- $ (10,000)(1) $ 516,047
Allowance for Inventory Obsolescence $ 705,103 $372,375 -- $ (82,225)(1) $ 995,253
Deferred Tax Asset Valuation Allowance $2,000,000 $649,000 -- -- $2,649,000
Year Ended December 31, 1998
Allowance for Doubtful Accounts $ 267,579 $ 3,965 -- -- $ 271,544
Allowance for Inventory Obsolescence $ 589,772 $266,838 -- $(151,507)(1) $ 705,103
Deferred Tax Asset Valuation Allowance $2,000,000 -- -- -- $2,000,000
Year Ended December 31, 1997
Allowance for Doubtful Accounts $ 274,766 $ 15,105 $10,714 $ (33,006)(1) $ 267,579
Allowance for Inventory Obsolescence $ 404,611 $417,787 -- $(232,626)(1) $ 589,772
Deferred Tax Asset Valuation Allowance $2,000,000 -- -- -- $2,000,000
(1) Relates to the write-off of accounts receivable or disposal of obsolete
inventory.
F-26
53
IRIS LOGO
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
9162 ETON AVENUE
CHATSWORTH, CA 91311
(818) 709-1244
54
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
EXHIBITS
TO
FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999
COMMISSION FILE NO. 1-9767
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
55
EXHIBIT INDEX
EXHIBIT
Exhibit Reference
Number Description Document
- ------ ----------- --------
3.1(a) Certificate of Incorporation, as amended (1)
3.1(b) Certificate of Designations of Series A Convertible Preferred Stock (2)
3.1(c) Certificate of Designations of Series B Callable Preferred Stock (3)
3.1(d) Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
3.2 Restated Bylaws (5)
4.1 Specimen of Common Stock Certificate (6)
4.2 Certificate of Designations of Series A Convertible Preferred Stock (2)
4.3 Certificate of Designations of Series B Callable Preferred Stock (3)
4.4 Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
10.1 Lease of the Company's headquarters facility, as amended (7)
10.2(d) 1994 Stock Option Plan and forms of Stock Option Agreements (8)
10.2(e) Certificate of Officer With Respect to Amendment of 1994 Stock Option Plan (9)
10.2(f) Employee Stock Purchase Plan --
10.2(g) 1997 Stock Option Plan and form of Stock Option Agreement (10)
10.2(h) 1998 Stock Option Plan and form of Stock Option Agreement (11)
10.3(a) Various Agreements with Sysmex Corporation, formerly TOA Medical Electronics Company, Ltd. (12)
10.3(b) Patent License Agreement dated April 1, 1997 between the Company and Sysmex Corporation, (13)
formerly TOA Medical Electronics Company, Ltd.
10.3(c) Amendment No. 1 to Patent License Agreement dated February 29, 2000 --
10.3(d) Termination, Release and Reassignment of Security Interest dated October 30, 1997 executed by (13)
Sysmex Corporation, formerly TOA Medical Electronics Company, Ltd. in favor of the Company
10.4(a) Agreement for a Strategic Alliance in Urinalysis dated January 7, 1994 between the Company and (14)
Boehringer Mannheim Corporation
10.4(b) Amendment to Distribution Agreements (15)
10.5(a) Technology License Agreement dated as of September 29, 1995 between the Company and Poly U/A (16)
Systems, Inc.
10.5(b) Research and Development Agreement dated as of September 29, 1995 between the Company and Poly (16)
U/A Systems, Inc.
10.5(c) $100 Class "A" Note dated September 29, 1995 issued by Poly U/A Systems, Inc. in favor of the (16)
Company
10.5(d) Form of Series D Warrant (13)
10.5(g) Form of Series E Warrant (13)
10.6(a) Registration Rights and Standstill Agreement dated July 31, 1996, between the Company and (9)
Digital Imaging Technologies, Inc.
10.6(b) Restated Warrant Certificates dated July 31, 1996 originally issued in connection with the
acquisition of Perceptive Scientific Instruments, Inc., to purchase 875,000 shares of
Common Stock of the Company --
10.6(c) Technology License Agreement dated July 31, 1996 between Perceptive Scientific Imaging Systems, (9)
Inc. and PSII Acquisition Corp., a wholly-owned subsidiary of the Company (now known as
Perceptive Scientific Instruments, Inc.)
10.7 $7,000,000 Subordinated Note dated July 29, 1996 issued by the Company in favor of Digital (9)
Imaging Technologies, Inc.
10.8(a) Loan and Security Agreement dated as of May 5, 1998 among the (17)
56
Company, Perceptive Scientific Instruments, Inc., and
StatSpin, Inc., on the one hand, and Foothill Capital
Corporation, on the other hand.
10.8(b) Intellectual Property Security Agreement dated as of May 5, 1998 between the Company and (17)
Foothill Capital Corporation
10.8(c) Copyright Security Agreement dated as of May 5, 1998 between the Company and Foothill Capital (17)
Corporation
10.8(d) Intellectual Property Security Agreement dated as of May 5, 1998 between Perceptive Scientific (17)
Instruments, Inc. and Foothill Capital Corporation
10.8(e) Copyright Security Agreement dated as of May 5, 1998 between Perceptive Scientific Instruments, (17)
Inc. and Foothill Capital Corporation
10.8(f) Security Agreement -- Stock Pledge dated as of May 5, 1998 between Perceptive Scientific (17)
Instruments, Inc. and Foothill Capital Corporation
10.8(g) Intellectual Property Security Agreement dated as of May 5, 1998 between StatSpin, Inc. and (17)
Foothill Capital Corporation
10.8(h) Amendment Number One to Loan and Security Agreement dated as of March 23, 1999 among the (18)
Company, Perceptive Scientific Instruments, LLC, and StatSpin, Inc., on the one hand, and
Foothill Capital Corporation, on the other hand
10.8(i) Amendment Number One to Security Agreement -- Stock Pledge dated as of March 23, 1999 among the (18)
Company and Perceptive Scientific Instruments, LLC, on the one hand, and Foothill Capital
Corporation, on the other hand
10.8(j) Amendment to Copyright Security Agreement dated as of March 23, 1999 among the Company and (18)
Perceptive Scientific Instruments, LLC, on the one hand, and Foothill Capital Corporation, on
the other hand
10.8(k) Amendment to Intellectual Property Security Agreement dated as of March 23, 1999 among the (18)
Company and Perceptive Scientific Instruments, LLC, on the one hand, and Foothill Capital
Corporation, on the other hand
10.8(l) Amendment Number Two to Loan and Security Agreement dated as of March 19, 1999 among the (18)
Company, Perceptive Scientific Instruments, LLC, and StatSpin, Inc., on the one hand, and
Foothill Capital Corporation, on the other hand.
10.8(m) Amendment Number Three to the Loan and Security Agreement dated as of April 16, 1999 among
the Company, Perceptive Scientific Instruments, LLC, and StatSpin, Inc., on the one hand,
and Foothill Capital Corporation, on the other hand --
10.8(o) Warrant to Purchase Common Stock dated June 1, 1997 issued to City National Bank (13)
10.8(p) Warrant to Purchase Common Stock dated July 1, 1997 issued to City National Bank (13)
10.9(a) Common Stock Purchase Warrant dated December 31, 1996 issued to Thermo Amex Convertible Growth (2)
Fund I, L.P.
10.9(b) Registration Rights Agreement dated December 31, 1996 by and between the Company and Thermo (2)
AMEX Convertible Growth Fund I, L.P.
24 Consent of PricewaterhouseCoopers LLP --
27 Financial Data Schedule 1999 --
99 Disclosure Regarding Risk Factors And Forward-Looking Statements --
Exhibits followed by a number in parenthesis are incorporated by
reference to the similarly numbered Company document cited below:
(1) Current Report on Form 8-K dated August 13, 1987 and Quarterly Report on
Form 10-Q for the quarter ended September 30, 1993.
(2) Current Report on Form 8-K dated January 15, 1997.
(3) Quarterly Report on Form 10-Q for the quarter ended June 30, 1999.
(4) Current Report on Form 8-K dated January 26, 2000.
(5) Quarterly Report on Form 10-Q for the quarter ended September 30, 1994.
(6) Registration Statement on Form S-3, as filed with the Securities and
Exchange Commission on March 27, 1996 (File No. 333-002001).
(7) Annual Report on Form 10-K for the year ended December 31, 1989,
Quarterly Report on Form 10-Q for
57
the quarter ended September 30, 1993 and Annual Report on Form 10-K for
the year ended December 31, 1994.
(8) Registration Statement on Form S-8, as filed with the Securities and
Exchange Commission on August 8, 1994 (File No. 33-82560).
(9) Quarterly Report on Form 10-Q for the quarter ended June 30, 1996.
(10) Registration Statement on Form S-8, as filed with the Securities and
Exchange Commission on July 16, 1997 (File No. 333-31393).
(11) Registration Statement on Form S-8, as filed with the Securities and
Exchange Commission on October 9, 1998 (File No. 333-65547).
(12) Current Report on Form 8-K dated July 15, 1988 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 1995.
(13) Annual Report on Form 10-K for the year ended December 31, 1997.
(14) Annual Report on Form 10-K for the year ended December 31, 1994.
(15) Quarterly Report on Form 10-Q for the quarter ended September 30, 1996.
(16) Quarterly Report on Form 10-Q for the quarter ended September 31, 1995.
(17) Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.
(18) Annual Report on Form 10-K for the year ended December 31, 1998.